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ABSTRACT 
 
It has been proposed that the glucose sensing mechanism in the hypothalamus and 
hindbrain is similar to pancreatic β cells, and brain glucose sensing may be involved in the 
regulation of food intake. For the first part of the dissertation, it is proposed that molecules 
involved in β cell glucose sensing, including glucokinase (GK), glucose transporter GLUT2, 
sulfonylurea receptor-1 (SUR1), glucagon-like peptide-1 receptor (GLP-1R), and the 
feeding-related neuropeptide Y (NPY), are colocalized in specific areas in the hypothalamus 
and hindbrain. GK, GLUT2, SUR1, GLP-1R and NPY mRNA expression in ten discrete 
brain areas were quantified by real time RT-PCR, which will serve as an initial step for the 
next functional study. 
The second part of the dissertation has been focused on GLUT2 only and it is 
proposed that brain GLUT2 may play a role in the central glucose sensing, specifically, brain 
GLUT2 is regulated by energy / glucose status, and overexpression of GLUT2 in neuronal 
cells will alter cellular energy status and feeding-related neuropeptide expression. Under 
three conditions: in vivo, ex vivo and in vitro, GLUT2 mRNA was significantly upregulated 
in the area postrema (AP) in the two-week 50% underfed rats, and by 1 mM glucose in rat 
area postrema / nucleus of the solitary tract (AP/NTS) tissue culture as well as in N1E-115 
neuroblastoma cell culture. Next, rat liver GLUT2 were overexpressed in GT1-7 
neuroblastoma cells. Compared with control cells, GLUT2 overexpression resulted in 
significantly increased cellular ATP levels at 5 mM or higher glucose concentrations, greater 
inhibition of AgRP mRNA by 25 mM glucose, and attenuated AgRP mRNA stimulation by 
2DG. In summary, brain GLUT2 mRNA is upregulated by low energy and low glucose 
status; overexpression of GLUT2 in neuronal cells results in higher cellular energy status and 
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greater suppression of hunger signals at high glucose levels or during glucoprivation. The 
conclusion is that brain GLUT2 is likely to play a role in the central glucose sensing and may 
be involved in the regulation of food intake.  
 vi
CHAPTER 1 
INTRODUCTION 
 
Obesity is a condition characterized by excessive body fat. The prevalence of obesity 
has increased dramatically over the past few decades. The 1988-1994 NHANES study 
showed that an estimated 56% of U.S. adults were either overweight (33%) or obese (23%) 
(NHANES 1996). The initial results from the 1999 NHANES indicated that approximately 
61% of U.S. adults were overweight (35%) or obese (26%) (NHANES 1999). Obesity is not 
only a chronic disease by itself, but also an independent risk factor for many other chronic 
diseases such as cardiovascular diseases, type II diabetes, hypertension, hyperlipidemia and 
cancer (Bethesda 1998). Obesity and its associated diseases are costly; some of which are life 
threatening. Therefore, it is important to investigate the mechanism of obesity development 
in order to find effective ways to treat and prevent obesity and to help people maintain 
normal body weight. 
The current understanding of the etiology of obesity is incomplete. Many factors, 
including both genetics and environment, contribute to the development of obesity (Bethesda 
1998). When the interactions among these factors result in the long-term energy intake being 
greater than the energy expenditure, overweight and obesity will develop (Wolf and Tanner 
2002). 
Energy intake is associated with appetite and food intake, i.e. feeding behavior; 
energy expenditure is associated with physical activity and heat production. The brain plays 
an essential role in sensing energy status and in maintaining energy homeostasis (Schwartz, 
Woods et al. 2000). Glucose is the primary fuel for the brain tissue; the glucose sensing 
mechanism in the brain may play an important role in the maintenance of energy homeostasis 
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and glucose homeostasis (Levin, Dunn-Meynell et al. 1999; Penicaud, Leloup et al. 2002). 
Defect or dysfunction in the brain glucose sensing mechanism may result in abnormal energy 
status, leading to weight gain or weight loss.  A long-term weight gain will lead to obesity. 
This dissertation is mainly focused on the mechanisms underlying brain glucose 
sensing and how signals from glucose fluctuation were translated to regulate feeding-related 
neuropeptide expression. Previous studies suggest that the hypothalamus and the area 
postrema and nucleus of the solitary tract (AP/NTS) in the hindbrain are critical in brain 
glucose sensing and in the control of feeding behavior (Ritter, Slusser et al. 1981; Penicaud, 
Pajot et al. 1990; Navarro, Rodriquez de Fonseca et al. 1996; Lynch, Tompkins et al. 2000; 
Schuit, Huypens et al. 2001). Glucose transporter 2 (GLUT2), one of the glucose sensors in 
the pancreatic β cells, is also expressed in the hypothalamus and hindbrain AP/NTS. GLUT2 
in the brain may be regulated by energy status (Zhou, Roane et al. 2003; Bogacka, Roane et 
al. 2004) and blocking of brain GLUT2 may affect energy homeostasis (Leloup, Orosco et al. 
1998; Wan, Hulsey et al. 1998). Until now, the regulation of brain GLUT2 and the role of 
GLUT2 in the brain are not completely understood. 
The hypothesis for this work is that brain GLUT2 is likely to play a role in the central 
glucose sensing. To test the hypothesis, firstly, GLUT2 was localized in discrete nuclei in the 
hypothalamus and the hindbrain. Secondly, the regulation of brain GLUT2 was investigated 
by three experiments to examine GLUT2 mRNA responses to low energy status in underfed 
rat brain, and to different glucose status in ex vivo cultured brain tissue and in N1E-115 
neuroblastoma cell line. Lastly, GLUT2 was overexpressed in GT1-7 neuroblastoma cell 
line, and ATP and agouti-related peptide (AgRP) mRNA responses to glucose and 2-
deoxyglucose (2DG) were examined in these cells. There is no known report of the effect of 
low energy status on GLUT2 levels in the brain.  There is no known report showing direct 
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evidence of GLUT2 response to glucose status in in vitro and ex vivo. There is no known 
report of the neuropeptide response to GLUT2 overexpression in neuronal cell line. This 
dissertation will contribute to the understanding of the regulation of brain GLUT2 by energy 
and glucose status, and the role of brain GLUT2 in the central glucose sensing in the aspect 
of controlling ATP level and hunger signals like AgRP in neuronal cells.  
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CHAPTER 2 
REVIEW OF LITERATURE 
 
Central Regulation of Food Intake 
 Hypothalamic Control of Energy Homeostasis
 As reviewed by Schwartz et al (Schwartz, Woods et al. 2000), the hypothalamus 
plays a critical role in the control of energy homeostasis. A number of feeding related 
neuropeptides are expressed in the specific nuclei in the hypothalamus. Based on their effect 
on energy homeostasis, these neuropeptides can be divided into two groups: orexigenic and 
anorexigenic. The orexigenic neuropeptides stimulate energy intake and inhibit energy 
expenditure; and the anorexigenic neuropeptides exert opposite effects. Examples of 
orexigenic peptides are neuropeptide Y (NPY), agouti-related peptide (AgRP), melanin-
concentrating hormone (MCH), orexins A and B (ORX). Examples of anorexigenic peptides 
are α-melanocyte-stimulating hormone (α-MSH), cocaine- and amphetamine-regulated 
transcript (CART), corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone 
(TRH). NPY and AGRP are co-localized in the arcuate NPY/AGRP neurons, α-MSH and 
CART are co-localized in the arcuate POMC/CART neurons, MCH and ORX neurons are 
localized in the lateral hypothalamus (LH), CRH and TRH neurons are localized in the 
paraventricular nucleus (PVN). Neuropeptides or receptor knockout studies indicate that 
some neuropeptides are redundant and can be compensated whereas others are more 
essential. For example, NPY knockout mice, AgRP knockout mice, or NPY/AgRP double 
knockout mice exhibits normal food intake and body weight (Qian, Chen et al. 2002). On the 
other hand, mice lacking MCH are hypophagic and lean (Shimada, Tritos et al. 1998), and 
mice lacking α-MSH receptor MC4R are hyperphagic and obese (Huszar, Lynch et al. 1997). 
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In the hypothalamus, the first order neurons in the arcuate integrate multiple inputs 
from peripheral (such as leptin and insulin) and the hindbrain, then send out signals to second 
order neurons in the PVN and LH, which will stimulate or inhibit feeding. Second order 
neurons also accept inputs from peripheral and hindbrain, and there are feedback interactions 
between the first and second order neurons (Schwartz, Woods et al. 2000). Taken together, 
the hypothalamic control of energy homeostasis involves inter-dependent interactions 
between the hypothalamus and peripheral and hindbrain, and multiple neuropeptides serve as 
the effecter as well as regulator in this system to regulate energy homeostasis.  
 AMPK in the Hypothalamic Regulation of Feeding 
 AMP-activated protein kinase (AMPK) has been known as a cellular energy sensor, 
and an increase in AMP to ATP ratio induces AMPK phosphorylation and activates AMPK 
(Hardie, Carling et al. 1998). AMPK has been proposed to be an energy sensor and regulator 
of food intake in the hypothalamus (Andersson, Filipsson et al. 2004; Kim, Miller et al. 2004; 
Kim, Park et al. 2004; Landree, Hanlon et al. 2004; Lee, Li et al. 2005; Minokoshi, Alquier et 
al. 2004). In the hypothalamus, AMPK activity is suppressed by glucose (i.p or ICV), 
refeeding, leptin, and insulin; on the other hand, AMPK activity is stimulated by low glucose, 
2DG and ghrelin. Activation of hypothalamic AMPK by overexpression of constitutively 
active AMPK or ICV injection of AMPK activator AICAR (5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside) increases food intake and body weight gain (Andersson, 
Filipsson et al. 2004; Minokoshi, Alquier et al. 2004); whereas inhibition of hypothalamic 
AMPK by overexpression of dominant negative AMPK or ICV injection of AMPK inhibitor 
compound C decreases food intake and body weight gain, or attenuates 2DG-induced feeding 
(Kim, Park et al. 2004; Minokoshi, Alquier et al. 2004). C75 is a synthetic fatty acid synthase 
inhibitor; C75 administration (both i.p. and ICV) suppresses food intake in mice (Loftus, 
 5
Jaworsky et al. 2000). In the hypothalamus, C75 inhibits AMPK phosphorylation, and the 
inhibitory effect of C75 on food intake can be reversed by subsequent administration of the 
AMPK activator AICAR; suggesting that hypothalamic AMPK mediates the inhibitory effect 
of C75 on food intake (Kim, Miller et al. 2004). Taken together, AMPK in the hypothalamus 
plays an important role in energy sensing and regulation of food intake. 
AgRP-expressing Neuroblatoma Cells 
Agouti related peptide (AgRP), or agouti related transcript (ART), is an orexigenic 
neuropeptide that robustly stimulates food intake (Schwartz, Woods et al. 2000). In mice and 
rats, AgRP is mainly expressed in the brain and adrenal gland, and to a less extent in the lung 
and testis. In the brain, AgRP expression is localized in the arcuate nucleus and median 
eminence (Ollmann, Wilson et al. 1997; Shutter, Graham et al. 1997). In the arcuate nucleus, 
AgRP is colocalized with neuropeptide Y (NPY), which is another robust orexigenic 
neuropeptide (Shutter, Graham et al. 1997; Hahn, Breininger et al. 1998). In the 
hypothalamus, AgRP mRNA expression is increased about eight to ten fold in obese mouse 
model (ob/ob mice, db/db mice) compared with controls (Ollmann, Wilson et al. 1997; 
Shutter, Graham et al. 1997). Hypothalamic AgRP mRNA is stimulated by fasting and 2DG, 
and inhibited by leptin (Ollmann, Wilson et al. 1997; Mizuno, Makimura et al. 1999; Mizuno 
and Mobbs 1999; Sergeyev, Broberger et al. 2000; Bertile, Oudart et al. 2003). 
Overexpression of AgRP in transgenic mice leads to obesity (Ollmann, Wilson et al. 1997). 
ICV injection of AgRP increases food intake, and the stimulatory effect on food intake by a 
single dose of AgRP injection lasts a week, implicating that AgRP is a robust stimulator of 
food intake (Hagan, Rushing et al. 2000). AgRP effect on food intake involves antagonism to 
melanocortin receptor MC3R and MC4R (Ollmann, Wilson et al. 1997); other mechanisms 
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including opioid receptor and calcium flux may also be involved but are not well understood 
to date (Hagan, Rushing et al. 2000; Hagan, Rushing et al. 2001).  
Neuroblastoma cell lines have been used to investigate how energy and glucose status 
regulate the expression of orexigenic neuropeptides. N1E-115 cell is a mouse neuroblastoma 
cell line that express multiple neuropeptides and receptors, among which AgRP, MC3R, 
MC4R leptin OB-receptor, insulin receptor are expressed at relatively high levels (Roth, Yee 
et al. 2002). AgRP mRNA decreases in a dose-dependent manner in the N1E-115 cells when 
cultured in DMEM containing increasing concentrations of glucose (1, 2.5, 5, and 10 mM) 
(Lee, Li et al. 2005). In addition to the neuropeptides and receptors, GLUT2 mRNA has been 
detected at measurable levels by real time RT-PCR. N1E-115 cell will be a good in vitro 
system to examine the effect of glucose on GLUT2 mRNA expression for the purpose of this 
dissertation. 
GT1-7 cell is an immortalized hypothalamic GnRH (gonadotropin-releasing 
hormone) cell line (Mellon, Windle et al. 1990). GT1-7 cells express MC4R and MC3R 
(Khong, Kurtz et al. 2001). GT1-7 cells also express AgRP mRNA; AgRP mRNA in GT1-7 
cells decreases dose-dependently in response to an increasing glucose concentration in 
culture medium (Lee, Li et al. 2005). GLUT2 mRNA is not detected in GT1-7 cells by real 
time RT-PCR (Li, unpublished data). This cell line will be used for in vitro overexpression of 
GLUT2 and AgRP response to glucose and 2DG after GLUT2 overexpression will be 
determined. 
2DG, 5TG and Glucose as Manipulators of Energy Status 
2-Deoxyglucose (2DG), 5-thioglucose (5TG) and glucose have been used to 
manipulate glucose status in the brain. 2DG and 5TG are non-metabolizable glucose 
analogues. 2DG or 5TG competitively inhibits the intracellular metabolism of glucose and 
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induces glucoprivation. Injection of 2-DG (or 5TG) into the lateral cerebral ventricle 
stimulates feeding and hyperglycemia in rats; at the same dose, 2DG does not stimulate 
feeding when injected intravenously and subcutaneously into rats. Therefore, the increased 
food intake is due to the direct effect of 2DG on the brain (Miselis and Epstein 1975). 2DG 
stimulates feeding by induction of NPY / AgRP expression in the arcuate nucleus and MCH 
expression in the lateral hypothalamus (Sergeyev, Broberger et al. 2000). Central glucose 
injection has been used to suppress food intake in rats. Infusion of glucose in the third 
ventricle of the rat brain over a period of seven days reduces both food intake and body 
weight. This amount of glucose does not change blood glucose level, suggesting that the 
depressed food intake is due to the effect of glucose on the brain (Davis, Wirtshafter et al. 
1981). Central administration of 2DG, 5TG or glucose can be used to manipulate brain 
glucose status and to change feeding behavior. 
Involvement of Hypothalamus and Hindbrain in Glucoprivic Feeding 
The hypothalamus is not necessary for 2DG-induced glucoprivation. 2DG directly 
injected into the LH and VMH fails to induce feeding in the rats (Miselis and Epstein 1975). 
Injection of 5TG into 61 specific hypothalamic areas fails to induce hyperglycemia and 
feeding in all of the areas studied, including arcuate nucleus, ventromedial nucleus, 
dorsomedial nucleus, paraventricular nucleus, and lateral hypothalamic area (Ritter, Dinh et 
al. 2000). Taken together, hypothalamus is not the primary site for glucoprivic feeding. 
The hindbrain is necessary for glucoprivic feeding. Injection of 5TG into the lateral or 
fourth ventricle stimulates feeding. When the aqueduct connecting the third and fourth 
ventricle is blocked, subsequent injection of 5TG into the lateral ventricle fails to stimulate 
feeding, yet injection of 5TG into the fourth ventricle still stimulates feeding (Ritter, Slusser 
et al. 1981; Penicaud, Pajot et al. 1990). Lesions of area postrema in the hindbrain blocked 
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2DG or 5TG induces glucoprivic feeding, suggesting that area postrema is a critical area for 
glucoprivic feeding (Contreras, Fox et al. 1982; Bird, Cardone et al. 1983). 
To further identify specific areas in the hindbrain responsible for glucoprivic feeding, 
Ritter et al (Ritter, Dinh et al. 2000) tested glycemic and feeding response to microinjection 
of 5TG (24ug in 200nl) in 142 hindbrain areas. 46% of tested hindbrain areas show positive 
glycemic and feeding response to 5TG, with an average increase of 75.9 mg/dl in blood 
glucose and 2.8 g in food intake for all positive sites. The positive sites are mainly located in 
the ventrolateral and dorsomedial medulla (including NTS), and more in the caudal than the 
rostral part of hindbrain, with almost complete overlapping of the sites showing positive 
glycemic and feeding response. Taken together, hindbrain is necessary for glucoprivic 
feeding. 
Brain Glucose Sensing 
Brain Glucose Levels 
Brain glucose level changes parallel with blood glucose level. Extracellular glucose 
concentration in the brain (cortex) can be measured by using a microelectrode. In normal 
Wistar rats, when blood glucose concentration is 7.6 mM, the corresponding glucose 
concentration in the brain is 2.4 mM. During hyperglycemia induced by intraperitoneal 
injection of glucose, the brain glucose concentration increases to 4.5 mM when blood 
glucose reaches 15.2 mM. During hypoglycemia induced by insulin injection, brain glucose 
concentration decreases to 0.16 mM when blood glucose lowers to 2.8 mM. At 
normoglycemia to hyperglycemia, brain glucose is about 31% of blood glucose level; at 
hypoglycemia, brain glucose drops to about 10% of blood glucose level (Silver and 
Erecinska 1994). Recordings of extracellular glucose concentration in ventromedial 
hypothalamus (VMH) by microdialysis show consistent results. VMH glucose is 18% of 
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blood glucose (1.42 mM vs. 7.7 mM) in fed rats; VMH glucose is 13% of blood glucose 
(0.73 mM vs. 5.8 mM) in fasted rats (de Vries, Arseneau et al. 2003). Taken together, brain 
glucose level is 10 % to 30% of blood glucose level, and brain glucose changes parallel with 
blood glucose under different glycemic conditions. 
Glucose Sensing Neurons in the Hypothalamus and Hindbrain 
Hypothalamus and hindbrain area postrema and nucleus of the solitary tract 
(AP/NTS) contain glucose-sensing neurons (Anand, Chhina et al. 1964; Oomura, Kimura et 
al. 1964; Mizuno and Oomura 1984; Riediger, Schmid et al. 2002). Neurons that increase 
firing as glucose levels increase were glucoreceptor (GR) neurons; neurons that decrease 
firing as glucose levels increase were glucose-sensitive neurons (GS). In the hypothalamus, 
GR neurons were mainly located in the ventromedial hypothalamus, and GS neurons were 
mainly located in the lateral hypothalamus (Oomura 1983). It is hypothesized that during 
hyperglycemia, increased glucose enters the neurons, being metabolized, leading to increased 
intracellular ATP concentration. Increased ATP inhibits ATP-sensitive K channel and 
activates GR neurons; increased ATP can also stimulate Na/K ATPase and inhibit GS 
neurons (Silver and Erecinska 1998; Song, Levin et al. 2001). 
Silver et al further categorized the glucose sensing neurons in the hypothalamus 
(Silver and Erecinska 1998). In the lateral hypothalamic area (LHA), 33% of neurons 
responded change in glucose levels, of which 93 – 95 % neurons are inhibited by a rise in 
glucose levels, i.e. GS neurons, and only 5 – 7 % are stimulated by a rise in glucose levels, 
i.e. GR neurons. GS neurons are divided into three types: type I neurons (about 60%) 
completely stop firing when blood glucose are between 10 – 12 mM; type II neurons stop 
firing when blood glucose is about 17 mM; and type III neurons keep firing at a lower rate 
when blood glucose is higher than 17 mM. All VMH neurons in this study increase firing 
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when blood glucose increases, i.e. GR neurons, most of which keep high firing rates when 
blood glucose was higher than 15 mM. When blood glucose is lowered to 3 – 4 mM, more 
than 90% of VMH GR neurons stop firing. 
Song et al studied VMH glucose sensing neurons from brain slices and defined 5 
types of neurons in the VMH (Song, Levin et al. 2001). The primary two types are glucose-
excited (GE neuron, i.e. classic GR neuron) and glucose-inhibited (GI neuron, i.e. classic GS 
neuron), which are inhibited or excited when extracellular glucose levels decrease from 2.5 
mM or 5 mM to 0.1 mM. In addition, they identified three types of presynaptic glucose 
sensing neurons, which change firing status by presynaptic inputs coming from other glucose 
sensing neurons. These neurons are: PDE neurons that can be presynatically excited by 
decreased glucose levels, PER neurons that can be presynaptically excited by increased 
glucose levels, and PIR neurons that can be presynaptically inhibited by increased glucose 
levels.  
Glucose sensing neurons have also been identified in the hindbrain AP/NTS area 
(Mizuno and Oomura 1984; Riediger, Schmid et al. 2002). Twenty-six percent of the NTS 
neurons examined in the brainstem slices responds to changes in glucose levels; of which 
76% decrease neuronal activity (GS neuron) and 24% increase neuronal activity (GR neuron) 
when glucose levels increase from 3 mM to 10 mM. The caudal part of NTS contains more 
glucose-responding neurons than the rostral part of NTS (Mizuno and Oomura 1984). In the 
AP, 53% of the neurons respond to changes in glucose levels, and all of them decrease 
activity at decreased glucose levels (GR neuron) (Riediger, Schmid et al. 2002). Taken 
together, hypothalamus and AP/NTS contain glucose sensing neurons that alter neuronal 
activity in response to fluctuation of blood glucose levels. 
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The Role of Glucose Metabolism in Neuronal Glucose Sensing 
The role of glucose metabolism in the mechanism of neuronal glucose sensing has 
been examined in the glucose responsive (GR) neurons in the VMH (Yang, Kow et al. 1999). 
GR neurons in the VMH increase firing when glucose is changed from 5 mM to 20 mM, but 
not from 1 mM to 5 mM. The stimulatory effect of glucose on the VMH GR neurons is 
blocked by simultaneous addition of 2DG, glucokinase inhibitor glucosamine, glucose 
transporter inhibitor phloridzin, and glyceraldehyde phosphate dehydrogenase (GAPDH) 
inhibitor iodoacetic acid. On the other hand, glucose effect on GR neurons can be mimicked 
by glycolytic intermediate glyceraldehyde and lactate, but not pyruvate. These results suggest 
that glucose metabolism is necessary for stimulation of GR neuron activity. Sulphonylurea 
tolbutamide can also stimulate GR neurons, indicating the existence of ATP-sensitive K 
channel. Despite some differences, VMH GR neurons exhibit a great similarity to the 
pancreatic β cells in terms of glucose sensing, such as requirement for glucose metabolism 
and the presence of KATP channel. 
The role of glucose metabolism in the inhibitory effect on neuronal activity is also 
examined in the GS neurons in the VMH (Yang, Kow et al. 2004). VMH GS neurons are 
inhibited when glucose is changed from 5 mM to 20 mM. Inhibitors of glucose transport 
(phloridzin), glucokinase (glucosamine), or glycolytic enzyme GAPDH (iodoacetic acid) 
block the inhibitory effect of glucose on GS neurons. Glycolytic intermediates 
glyceraldehyde and lactate, but not pyruvate, can mimic the inhibitory effect of glucose on 
GS neurons. 2DG blocks the inhibitory effect of glucose on GS neurons, and even activates 
GS neurons in the presence of 20 mM glucose. Unlike GR neurons, tolbutamide has no effect 
on GS neurons, indicating that the KATP channel is not necessary for glucose inhibition of GS 
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neurons. Taken together, glucose metabolism is required for the inhibitory effect of glucose 
on GS neurons in the VMH.  
Hypothalamic Glucose Sensing Model 
As mentioned above, glucose sensing neurons, especially GR neurons, exhibit a great 
similarity to pancreatic β cells. In addition, the β cell glucose sensing components, GLUT2, 
βGK, and KATP channel have been identified in the hypothalamus (Navarro, Rodriquez de 
Fonseca et al. 1996; Yang, Kow et al. 1999; Schuit, Huypens et al. 2001). The highest 
expression of GK in the brain is in the arcuate nucleus and VMH (Lynch, Tompkins et al. 
2000). A model for glucose sensing in the hypothalamus has been proposed based on the β 
cell model (Schuit, Huypens et al. 2001). In this model, glucose metabolism through 
glycolysis is necessary for signaling neuronal activity. As in the β cells, GK is likely rate 
limiting in the glucose flux through glycolysis, leading to proportional generation of ATP. 
Increased ATP/ADP ratio results in closure of KATP channels and triggers firing of GR 
neurons. In addition to glucose, the hypothalamic glucose sensing neurons may interact with 
endocrine signals from insulin and leptin to regulate energy intake and energy expenditure 
(Spanswick, Smith et al. 1997; Spanswick, Smith et al. 2000). 
The Pancreatic β Cell Glucose Sensing and Insulin Secretion Model 
The pancreas is an important peripheral glucose-sensing organ. Pancreatic β cells can 
detect fluctuation of blood glucose level and respond by regulation of insulin/glucagon 
secretion.  Previous findings have demonstrated that glucokinase (GK), glucose transporter 2 
(GLUT2) and ATP-sensitive potassium (KATP) channels are required for normal glucose 
sensing and insulin secretion in pancreatic β cells. GLUT2 (Km = ~ 17 mM for glucose) 
plays a permissive role and allows rapid glucose entry into pancreatic β cells (Thorens 2001). 
GK is the rate-limiting enzyme of glycolysis and regulates the rate of glucose metabolism in 
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β cells (Matschinsky, Liang et al. 1993). Glucose enters the β cells via GLUT2 and is 
metabolized through glycolysis, resulting in the generation of ATP. Increased intracellular 
ATP closes ATP-sensitive potassium channels on the membrane of β cells, and the resultant 
decrease in the efflux of potassium leads to depolarization of the β cells, opening of voltage-
sensitive calcium channels, influx of calcium and secretion of insulin (Kieffer and Habener 
2000). In addition to glucose metabolism that can induce insulin secretion, other factors such 
as glucagon-like peptide-1 (GLP-1) can also induce insulin secretion (Drucker 1998; Drucker 
2001). The components of β cell glucose sensing apparatus, including GLUT2, βGK, KATP 
channel, have been detected in specific brain areas involved in the regulation of food intake 
(Leloup, Arluison et al. 1994; Karschin, Ecke et al. 1997; Lynch, Tompkins et al. 2000). And 
it has been proposed that brain glucose sensing neurons use a similar mechanism like β cell 
glucose sensing model (Schuit, Huypens et al. 2001). Next, GLUT2, βGK, KATP channel, 
GLP-1 and GLP-1 receptor will be reviewed individually on their involvement in the β cell 
glucose sensing, their expression in the brain and proposed role in the brain glucose sensing 
and regulation of food intake, with an emphasis on GLUT2 and GK. 
Glucokinase (GK) 
GK Overview 
GK, also referred to as type IV kexokinase, converts glucose to glucose-6-phosphate 
as the first step of glycolysis. Unlike hexokinase I, II, and III, GK has a high Km (~ 10 mM) 
for glucose and lacks the feedback inhibition by end product glucose-6-phosphate. 
Peripherally, it has been long established that GK is expressed in the liver and pancreatic 
islets β cells (Andreone, Printz et al. 1989; Magnuson, Andreone et al. 1989; Magnuson and 
Shelton 1989). In addition, GK is also identified in the pancreatic islet α cells (Heimberg, De 
Vos et al. 1996) and intestinal endocrine cells (Jetton, Liang et al. 1994). Liver GK (LGK) 
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and β cell GK (βGK) are transcribed under different promoters, resulting in tissue-specific 
GK isoforms in the liver and β cells, which differ in their sequence of N-terminal amino 
acids (Magnuson and Shelton 1989). Pancreatic islet α cell GK mRNA and protein are same 
as βGK (Heimberg, De Vos et al. 1996). In the gut, GK transcription is under the same 
promoter as βGK (Jetton, Liang et al. 1994). 
Liver GK 
Liver GK is responsible to quickly phosphorylate glucose and direct glucose to 
glycogen synthesis and lipogenesis after a meal. In the liver, glucose metabolism regulates 
the expression of glycolytic and lipogenic enzymes, such as pyruvate kinase and fatty acid 
synthase in a dose-dependent manner. LGK plays a key role in regulating liver glucose 
metabolism, and is required for glucose induction of glycolytic and lipogenic enzymes 
(Girard, Ferre et al. 1997). Consistently, fasted rats with GK overexpression in the liver show 
increased pyruvate kinase activity similar to control fed rats. This also demonstrates that GK 
is the rate-limiting step in liver glucose utilization and glucose-regulated glycolytic enzyme 
expression (Ferre, Riu et al. 1996; Scott, Collier et al. 2003). Liver specific GK knock out 
does not affect animal survival. The LGK knock out mice show a 10% increase in plasma 
glucose and doubled plasma insulin in the fed state, indicating insulin resistance. During 
hyperglycemic clamp, these mice show 30% of glucose turnover and 10% of liver glycogen 
synthesis ability compared with control mice, suggesting impaired liver glucose disposal 
(Postic, Shiota et al. 1999). The above evidence indicates that LGK plays an important role in 
liver glucose metabolism and in the whole body glucose homeostasis. 
Insulinoma-bearing rats develops hyperinsulinemia and hypoglycemia after 2-3 
months of insulinoma implantation. In these rats, LGK activity is 4-fold that of control. 
Glucose infusion for 24 h brings glucose levels back to 10 mM, but has no effect on LGK 
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activity. Removal of insulinoma brings glucose and insulin back to normal level, LGK 
activity decreases to control level by day 6 after insulinoma removal (Bedoya, Matschinsky 
et al. 1986). LGK mRNA increases 20-fold and 30-fold in diabetic rats after infusion of 
insulin for 2 and 4 h, respectively (Magnuson, Andreone et al. 1989; Magnuson and Shelton 
1989). In 2-day fasted rats, a single dose of glybenclamide (0.1 mg / kg body weight) (close 
K-ATP channel and induce insulin secretion) induces a 4-fold increase in LGK mRNA 
within 1 h; the induction of LGK mRNA is abolished by concomitant administration of 
diazoxide (open K-ATP channel and antagonize insulin secretion) with glybenclamide 
(Tiedge and Lenzen 1995). The above evidence suggests that LGK is regulated at the 
transcriptional level by insulin but not glucose. 
Regulatory Protein of Glucokinase (GKRP) 
Liver GK is also regulated by glucokinase regulatory protein (GKRP). GKRP is 
mainly located in the nucleus of the hepatocytes. At normal glucose concentrations (5 mM), 
GK binds to GKRP and is retained in the nucleus; at high glucose concentrations (10-30 
mM) or in the presence of low concentrations of fructose (50 uM to 1 mM), GK is released 
and translocates into the cytoplasma for glucose phosphorylation (Agius and Peak 1993; Van 
Schaftingen 1994; Van Schaftingen, Detheux et al. 1994; Agius, Peak et al. 1995; Brown, 
Kalinowski et al. 1997). Binding of GKRP to GK inhibits GK activity. Adenovirus-mediated 
overexprsssion of GKRP in the isolated hepatocytes increases bound GK and decreased free 
GK. GKRP overexpression inhibits free GK activity, glucose phosphorylation, glycolysis and 
glycogen synthesis (de la Iglesia, Mukhtar et al. 2000). The effect of GKRP deficiency is also 
investigated by using GKRP knockout mice. GKRP deficient mice show absence of GK 
anchored to the nucleus in the liver cells (Farrelly, Brown et al. 1999; Grimsby, Coffey et al. 
2000). Compared with wild-type mice, the homozygous (GKRP-/-) and heterozygous 
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(GKRP+/-) GKRP knockout mice have similar basal blood glucose and insulin levels. After a 
glucose load, the GKRP-/- mice show moderately impaired glucose tolerance. At 5 mM 
glucose, GK activity in the liver homogenates from GKRP-/- and GKRP+/- mice is not 
different from controls. At 50 mM glucose, GK protein is decreased by 75% and 30%; 
whereas GK mRNA is increased by 1.7- and 2.1-fold in GKRP-/- and GKRP+/- mice, 
compared with control. The decrease in GK protein is not due to decreased GK transcription. 
GKRP knockout study suggests that GKRP binding to GK serves as a “functional reserve” 
for GK to be activated by metabolic milieu, and GKRP may also helps stabilize live GK 
protein (Grimsby, Coffey et al. 2000). Consistently, another GKRP-mutant study shows that 
GK protein and activity are decreased in the liver of GKRP-mutant mice. The GKRP-mutant 
mice also show impaired glucose tolerance. In the GKRP-mutant mouse liver, insulin 
stimulates GK mRNA but fails to increase GK protein, supporting that GKRP regulates liver 
GK expression at the posttranscriptional level (Farrelly, Brown et al. 1999). In support that 
GKRP may help stabilize GK, adenovirus-mediated GKRP and GK are overexpressed in the 
HepG2 cells, which do not express endogenous GK and GKRP. Cells with both GKRP and 
GK overexpression have higher GK protein and enzymatic activity than cells with only GK 
overexpression, suggesting that GKRP may help to stabilize or protect GK (Slosberg, Desai 
et al. 2001). Taken together, GKRP binds to and localize liver GK in the nucleus in an 
inactive status. The GKRP-GK complex serves as a reservoir and releases GK in response to 
metabolic stimuli. GKRP also plays a regulatory role in the liver GK protein expression at 
the posttranscriptional or posttranslational level, and GKRP may help stabilize GK as well. 
GKRP mRNA and protein are also identified in the pancreatic islets and 
hypothalamus (Alvarez, Roncero et al. 2002). In addition to liver isoform of GKRP, two 
alternative splicing isoforms of GKRP are also found in the liver, pancreatic islets and 
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hypothalamus. Like in the liver, brain GKRP can be co-precipitated with GK, indicating that 
GKRP interacts with GK in the brain. In the brain, GKRP and GK are mainly in the soluble 
and nuclear fractions, similar as that of liver. However, whether GKRP in the pancreatic islet 
and in the hypothalamus play a regulatory role on GK as in the liver is still unknown. 
GKRP overexpression in the liver may be used as a tool to treat type II diabetes. In a 
type II diabetic mouse model, GKRP overexpresssion in the liver is achieved by injection of 
adenovirus containing human GKRP through tail vein. Three weeks after injection, the 
diabetic mice with GKRP overexpression in the liver show lowered blood glucose similar to 
that of non-diabetic control mice, as well as improved glucose tolerance, implicating the 
possibility of GKRP as a treatment for type II diabetes (Slosberg, Desai et al. 2001). 
β Cell GK 
βGK has been known as the pancreatic β cell glucose sensor (Matschinsky, Liang et 
al. 1993; Postic, Shiota et al. 2001). βGK phosphorylation of glucose is the rate-limiting step 
in glycolysis in the β cells, and βGK determines the rate of glucose metabolism in the β cells, 
which proportionally reflects blood glucose levels. In this way, βGK acts as a glucose sensor 
and couples glucose metabolism to insulin secretion. 
βGK has also been proposed as a diabetes candidate gene (Matschinsky, Liang et al. 
1993; Postic, Shiota et al. 2001). Mutations in GK have been identified as the cause of 
MODY2 (maturity onset diabetes of the young) in humans. MODY2 is autosomal dominant, 
familial inherited and has mutations in one allele of GK gene. Patients with MODY2 are 
characterized by early age onset of type II diabetes, impaired GK enzymatic activity, and a 
rightward shift of the glucose stimulated insulin secretion curve (Velho and Froguel 1998). 
Animal model for MODY has been generated by disruption of exon 2 of GK gene (Bali, 
Svetlanov et al. 1995). Heterozygous mice with GK mutations (GK+/-) show similar 
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characteristics like that of MODY, including reduced both βGK and LGK enzymatic activity, 
mildly elevated fasting glucose levels, and impaired glucose tolerance as revealed by 
hyperglycemic clamp. To specify the role of βGK, βGK knockout mice has been generated 
by disruption of exon 1β of GK gene, and liver GK is intact in these mice (Terauchi, Sakura 
et al. 1995). The homozygous (GK-/-) mice die within seven days after birth due to severe 
diabetes. The heterozygous (GK +/-) mice show mild glycosuria within a day after birth 
suggesting early onset, and significant increase in blood glucose levels and impaired glucose 
tolerance at ten weeks of age, suggesting diabetes. This study indicates that homozygous 
βGK mutation is lethal, and heterozygous βGK mutation is sufficient to cause diabetes like 
MODY. Postic et al (Postic and Magnuson 1999) have produced another β cell GK specific 
knock out mouse model by using Cre-LoxP system. Consistently, most of the homozygous 
βGK knockout mice (βGK-/-) die of severe diabetes within a week after birth; and the 
heterozygous βGK knockout mice (βGK+/-) can survive. In contrast, both homozygous and 
heterozygous liver GK knockout mice survive. At six to ten weeks of age, the βGK+/- mice 
are moderately hyperglycemic, and demonstrate reduced insulin secretion (by 70%), glucose 
turnover (by 60%) and glucose infusion rate (by 70%) during hyperglycemic clamp. Taken 
together, βGK plays an indispensable role in the whole body glucose homeostasis.  
βGK is differentially regulated from liver GK. An insulinoma-bearing rat model has 
been generated by subcutaneous implantation of a small fragment of insulinoma (Bedoya, 
Matschinsky et al. 1986). Two to three months later, the insulinoma-bearing rats show 
hyperinsulinonemia and hypoglycemia, and βGK activity is only about 30% in the islets 
compared with control. After 24 h 50% glucose infusion, βGK activity doubles and reaches 
50% of controls. βGK activity is fully recovered to control level 24 h after removal the 
insulinoma when hypoglycemia has been corrected. This study suggests that glucose plays a 
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primary role in the regulation of βGK. In two-day fasted rats, oral glucose (4 g / kg body 
weight) induces βGK mRNA three-fold within 1 h (Tiedge and Lenzen 1995). βGK mRNA 
in the isolated rat islets incubated in 10 mM glucose increases to 2.8-fold of that incubated in 
2 mM glucose. This evidence further supports that glucose regulates βGK gene expression. 
Glucose also regulates enzymatic activity of βGK at the post-translation level. 
Pancreatic islets cultured in 10 mM glucose show 116% increase in βGK enzyme activity 
compared with 2 mM glucose (Tiedge, Steffeck et al. 1999). Evidence for whether glucose 
induces βGK translocation does not agree very well. Noma et al show that glucose infusion 
(1 g / kg body weight) rapidly induces a translocation of βGK from a perinuclear position 
into the cytoplasm in rat islets (Noma, Bonner-Weir et al. 1996). By using GK 
overexpressing insulin-secreting RINm5F cells, Tiedge et al show that GK exists in two 
fractions: a bound fraction with low enzyme activity and a diffusible fraction with high 
activity; and glucose induces a significant increase in the diffusible GK fraction with high 
enzyme activity. A regulatory protein that may regulate βGK activity in response to glucose 
has been suggested, and this protein is not identical to liver GKRP as revealed by Northern 
Blot (Tiedge, Steffeck et al. 1999). In another study, a glucose-responsive insulin secreting β 
cells line, MIN6 cells are used to examine the post-translation regulation of glucose on GK. 
In the MIN6 cells, GK exists in the cytoplasm as well as in granules; 25 mM glucose fails to 
induce a rapid change in the subcelluar localization of GK compared with 5 mM glucose, and 
therefore argues against the existence of liver GKRP like regulatory protein (Stubbs, Aiston 
et al. 2000). On the other hand, both mRNA and protein of GKRP have been reported to exist 
in the pancreatic islets, and this GKRP can interact with GK (Alvarez, Roncero et al. 2002). 
In summary, glucose stimulates βGK enzyme activity. It is still inconclusive whether glucose 
 20
induces translocation and release of GK in an active status, and whether βGK is regulated by 
a liver GKRP-like protein in a glucose-dependent manner. 
Small Molecule GK Activators 
A small molecule GK activator (GKA) has been synthesized based on the screening 
of a library of 120,000 synthetic compounds. GKA dose-dependently increases GK activity 
and reverses the inhibition of GK by GKRP. GKA lowers the threshold concentration of 
glucose to induce insulin secretion in freshly isolated rat pancreatic islets (from 7 mM to 3   
mM). A single oral dose of GKA lowers blood glucose in wild type and type II diabetic 
C57BL/6J mice. The decrease in blood glucose is accompanied with an increase in blood 
insulin in the wild type mice. Glucose tolerance test shows that GKA improves glucose 
tolerance in ob/ob and diet-induced obese mice. GKA also exerts a favorable effect on liver 
by increasing hepatic glucose uptake and inhibiting endogenous glucose production 
(Grimsby, Sarabu et al. 2003). The above evidence suggests that GKA can be a potential 
anti-hyperglycemia and anti-diabetic drug.  
GK in the Brain 
Jetton et al first analyzed the upstream GK promoter activity in the transgenic mouse 
brain. The upstream GK promoter is the β cell GK promoter. In the brain of the transgenic 
mice, the upstream GK promoter activity is detected in the pituitary and medial 
hypothalamus, RNA-PCR showed GK mRNA in the hypothalamus, cortex, brainstem and 
cerebellum (Jetton, Liang et al. 1994). This study demonstrates the existence of GK in the 
brain, and it is the βGK promoter that is active in the brain. Later on, two studies show that 
βGK but not liver GK is the predominant isoform of GK expressed in the hypothalamus by 
RT-PCR (Yang, Kow et al. 1999; Schuit, Huypens et al. 2001). Lynch and colleagues 
(Lynch, Tompkins et al. 2000) demonstrate the relative abundance of GK mRNA in the 
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hypothalamus and in the hindbrain by in situ hybridization and RT-PCR. In situ hybridization 
shows that the heaviest labeling for GK is in the arcuate nucleus and the ventromedial 
nucleus within the hypothalamus. Double labeling shows that more than 75% of NPY 
neurons in the arcuate nucleus co-express GK mRNA. RT-PCR shows the highest GK levels 
in the arcuate nucleus and the lateral hypothalamus and the lowest in the paraventricular 
nucleus. A more recent study (Dunn-Meynell, Routh et al. 2002) reports the presence of GK 
mRNA in AP/NTS by RT-PCR; furthermore, GK has been localized specifically in the 
neurons by double-labeling in situ hybridization. In summary, GK expression is “neuron-
specific” in the discrete hypothalamic and hindbrain areas; and βGK is the predominant 
isoform of GK in the brain. 
GK has been proposed as the likely “glucose sensor” in hypothalamic glucose-excited 
(GE) and glucose-inhibitory (GI) neurons (Dunn-Meynell, Routh et al. 2002). GE and GI 
neurons have been isolated from ventromedial hypothalamic nucleus. At 2.5 mM glucose, 
GE neurons are stimulated and GI neurons are inhibited; at 0.5 mM glucose, GE neurons are 
inhibited and GI neurons are stimulated. At 2.5 mM glucose, addition of selective GK 
inhibitors (alloxan, mannoheptulose, glucosamine or N-acetylglucosamine) result in 
inhibition of GE neurons and stimulation of GI neurons, suggesting that GK acts as a glucose 
sensor in these neurons. Injection of alloxan into the third ventricle, but not fourth ventricle, 
results in reduced food intake and hyperglycemic response to 2DG or 5TG. The destruction 
of tanyacytes and neuronal swelling after alloxan injection may be responsible for the above 
feeding and glycemic response. Upon the recovery of the tanyacytes, the feeding and 
glycemic response to glucoprivation are restored (Sanders, Dunn-Meynell et al. 2004). The 
conclusion from this report is that “neuronal substrates around third ventricle affected by 
alloxan” is responsible for the above response. However, it is also possible that some changes 
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have been induced by alloxan in the tanyacytes that result in the subsequent neuronal changes 
and behavioral changes. Alloxan is not a specific GK inhibitor; it may affect factors 
unknown at present. GLUT2 has been shown expressed in the tanyacytes along the third 
ventricle, and the tanyacytes in the median eminence (which is close to the bottom of the 
third ventricle) have direct contact with the neurons in the arcuate nucleus (Garcia, Millan et 
al. 2003). Therefore, the possibility of GLUT2 involvement in this response cannot be 
excluded. 
Glucose Transporter 2 (GLUT2) 
GLUT2 Overview  
Glucose transporter 2 (GLUT2) is a low affinity and high Km (~ 17 mM) facilitative 
glucose transporter, and GLUT2 transport of glucose is bi-directional. GLUT2 protein 
contains 522 amino acids; the predicted structure of GLUT2 consists of 12 membrane-
spanning domains with both the N-terminal and C-terminal in the cytoplasm. There is a 
single glycosylation site between the first and second membrane-spanning domain, and there 
is a large intracellular loop located between the membrane-spanning domains six and seven 
(Thorens, Sarkar et al. 1988; Olson and Pessin 1996). 
Peripherally, GLUT2 is expressed in the liver, pancreatic β cells, small intestine and 
kidney ((Thorens, Sarkar et al. 1988), tissues that require the high Km GLUT2 to rapidly 
transport glucose in proportion to physiological glucose concentrations. Unlike GK, GLUT2 
is not detected in the pancreatic α cells (Heimberg, De Vos et al. 1995).  
Liver GLUT2 
Thorens et al (Thorens, Flier et al. 1990) show that GLUT2 is the major glucose 
transporter in the liver. Liver GLUT2 protein is not changed after a two-day fasting and is 
increased 70% after refeeding. In contrast to the minimal changes in the protein, liver 
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GLUT2 mRNA is decreased 45% after two-day fasting and increased up to five fold after 
refeeding, compared with ad libitum controls. Liver GLUT2 protein and mRNA are not 
altered in streptozotocin-induced diabetic rats, either with or without insulin treatment. 
Compared with the more dramatic changes in liver GLUT2 mRNA by fasting and refeeding, 
GLUT2 protein changes within a small range. The rather constant level of GLUT2 protein is 
consistent with the role of GLUT2 in the liver as a bi-directional transporter for glucose. 
After feeding, GLUT2 transports glucose into the liver cells for metabolism, and during 
fasting period, GLUT2 transports glucose derived from glycogenolysis and gluconeogenensis 
out of liver cells to maintain blood glucose levels. 
The regulation of liver GLUT2 by metabolic alterations has also been investigated in 
isolated rat hepatocytes (Asano, Katagiri et al. 1992; Rencurel, Waeber et al. 1996). Glucose 
upregulates GLUT2 mRNA in a dose dependent manner in the hepatocytes; and there is a 
two-fold increase in GLUT2 mRNA at 27.8 mM glucose compared with no glucose. Fructose 
and mannose also upregulate GLUT2 mRNA in the hepatocytes (Asano, Katagiri et al. 
1992). The up-regulation of liver GLUT2 by glucose requires glucose metabolism and occurs 
at the transcriptional level (Rencurel, Waeber et al. 1996). Non-metabolizable glucose analog 
3-O-methylglucose and 2-deoxyglucose cannot stimulate GLUT2 mRNA in primary 
hepatocytes. Glucose induction of GLUT2 mRNA is abolished in cultured hepatocytes after 
blocking of glucose phosphorylation; dihydroxyacetone can stimulate GLUT2 mRNA in 
hepatocytes, whereas pyruvate and lactate cannot, indicating that a metabolite from glucose 
metabolism is needed for glucose stimulation of GLUT2. Glucose regulates GLUT2 at the 
transcription level by activating the proximal region of GLUT2 promoter. Taken together, 
liver GLUT2 is induced by glucose, which requires glucose metabolism, and the induction by 
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glucose involves regulation at transcription of GLUT2 mRNA by activation of GLUT2 
promoter.  
β Cell GLUT2 
GLUT2 is a glucose sensor in the pancreatic β cells. GLUT2 plays a permissive role 
in the β cells, allowing the uptake of glucose by β cells to be proportional to blood glucose, 
which is important because signals generated from glucose metabolism to regulate insulin 
secretion in the β cells has to reflect glucose fluctuation in the blood. In this sense, GLUT2 is 
essential for glucose stimulation of insulin secretion (GSIS). 
It had been proposed that defective glucose transporter in the β cells results in loss of 
GSIS, hyperglycemia, and noninsulin-dependent diabetes (NIDDM) (Johnson, Ogawa et al. 
1990; Unger 1991). This hypothesis is tested in a NIDDM animal model, Zucker diabetic 
fatty rats. In the diabetic Zucker rats, hyperglycemia (blood glucose > 11 mM) is associated 
with loss of GSIS, reduced glucose transport and decreased GLUT2 in the β cells. There is a 
negative relationship between hyperglycemia and the percentage of GLUT2-positive β cells; 
and GSIS is absent when the percentage of GLUT2-positive β cells is less than 60%. In 
addition, down-regulation of GLUT2 is not secondary to hyperglycemia. Hyperglycemia 
maintained for seven days in normal rats by continuous infusion of 50% glucose fails to 
down-regulate GLUT2 in β cells. In vitro, neonatal rat pancreas cultured in the presence of 
high glucose (33.4 mM) for five weeks even show increased GLUT2 protein. Prevention of 
hyperglycemia with acarbose (inhibitor of α-glucosidase) does not prevent the loss of 
GLUT2 in prediabetic Zucker rats (Orci, Ravazzola et al. 1990). Taken together, reduction of 
GLUT2 in the β cells results in defective glucose sensitivity and insulin response of β cells, 
and may play a role in the development of persistent hyperglycemia and NIDDM. 
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The role of GLUT2 in the β cells is further investigated using GLUT2-null mice 
(Guillam, Hummler et al. 1997).  The homozygous GLUT2-null mice have abnormal 
pancreatic islets development (inversion of α and β cell ratio), hyperglycemia, 
hypoinsulinemia, and impaired glucose tolerance (persistent hyperglycemia 90 min after 
glucose load). The GLUT2-negative islets show delayed and decreased insulin secretion to 
16.7 mM glucose. Glucose-stimulated insulin biosynthesis is also impaired in the GLUT2-
negative islets (Guillam, Hummler et al. 1997). Lentivirus-mediated GLUT2 re-expression in 
the GUT2-null islets restores the normal insulin secretion (Guillam, Dupraz et al. 2000). In 
another report (Thorens, Guillam et al. 2000), the GLUT2-null mice are re-expressed GLUT1 
or GLUT2 in pancreatic β cells by transgenic approach. Re-expression of either GLUT1 or 
GLUT2 restores the glucose tolerance and insulin secretory response during hyperglycemic 
clamp. In vitro, islet isolated from GLUT2-null mice with either GLUT1 or GLUT2 re-
expression show normal GSIS when treated with 16.7 mM glucose, in which the first phase 
of insulin secretion and the amplitude of insulin secretion are restored to control levels. One 
of the conclusions from this study is that it is the rate of glucose uptake at high glucose 
concentration that is important for normal GSIS. However, under physiological conditions, 
only GLUT2 has the high Km (~17 mM) that allows glucose transport into the β cells in 
proportion to blood glucose levels and in an unsaturated manner. The kinetic property of 
GLUT2 confers it as a glucose sensor for β cells. 
In contrary to the above study, an in vitro study using AtT-20ins cells shows that it is 
GLUT2, but not GLUT1 overexpression that enables the cells to secrete insulin in response 
to glucose stimulation (Hughes, Quaade et al. 1993). AtT-20ins cell line is derived from 
anterior pituitary and engineered to express human insulin. AtT-20ins cells overexpressing 
GLUT2 by transfection acquire the property of glucose stimulated insulin secretion, whereas 
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cells transfected with GLUT1 do not. Further examination shows that cells transfected with 
GLUT2 have a Km of 16-17 mM for 3-O-methyl glucose uptake, whereas cells transfected 
with GLUT1 have a Km of 4 mM, although glucose utilization is similar in both cells. The 
GLUT1 transfected cells do not reach a Km comparable to that of GLUT2, which explains 
the absence of GSIS, and emphasizes that it is the glucose uptake rate that is important in 
GSIS. On the other hand, the similar glucose utilization of both transfected cells suggestes 
that GSIS in the AtT-20 cells is not related to glucose metabolism, which raises the 
speculation that GLUT2 may signal to insulin secretion by other mechanisms in addition to 
glucose transport and the subsequent glucose metabolism in the β cells (Hughes, Quaade et 
al. 1993). This speculation is supported by the study with an engineered human hepatoma 
cell line. The hepatoma cells lack endogenous GLUT2 expression. After first transfection 
with insulin cDNA, the cells can synthesis, storage and release insulin to insulin 
secretagogues but not to glucose. After a second transfection with GLUT2 cDNA, the cells 
demonstrate GSIS. Surprisingly, ATP-sensitive potassium channel is induced in the insulin 
and GLUT2 double transfected cells (Liu, Simpson et al. 2003). Studies with pancreatic β 
cells suggeste that phosphorylation of the intracellular carboxyl terminal of GLUT2 protein 
may be involved in the stimulation of insulin secretion (Thorens, Deriaz et al. 1996).  In 
summary, GLUT2 acts as a glucose sensor in β cells through glucose transport function as 
well as other mechanisms unknown at present.  
 GLUT2 in the β cells is regulated by glucose. GLUT2 mRNA of β cells is reduced 
23%, 85%, and nearly 100% after 3-h, 4-day and 12-day hypoglycemia induced by insulin. 
Consistently, the islets from the rats after 12-day hypoglycemia lose the high Km for 3-O-
methylglucose transport, which decreases from 17-20 mM to 2.5 mM. After 5-day 
hyperglycemia induced by continuous glucose infusion, islet GLUT2 mRNA is increased 
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46% (Thorens, Deriaz et al. 1996). In vitro study (Ferrer, Gomis et al. 1993) shows that 
GLUT2 mRNA from islets cultured in 11 or 16.7 mM glucose is 10-fold of that from islets 
cultured in 2 mM glucose. Correspondingly, 16 mM glucose induces a 4-fold increase in islet 
GLUT2 protein. Addition of RNA and protein inhibitors prevent glucose stimulation of islet 
GLUT2, indicating that the effect of glucose on GLUT2 involves mRNA and protein 
synthesis. In the presence of glycolysis inhibitor mannoheptulose, 16 mM glucose fails to 
induce GLUT2 mRNA and protein; 2-deoxyglucose cannot stimulate GLUT2 expression, 
suggesting that glucose metabolism is required for its stimulatory effect on islet GLUT2. 
Altogether, β cell GLUT2 is regulated by glucose. 
GLUT2 in the Brain 
Leloup and colloegues (Leloup, Arluison et al. 1994) demonstrat that relatively high 
levels of GLUT2 mRNA are expressed in the nucleus of the solitary tract (NTS) and the 
motor nucleus of the vagus (MNV) by reverse transcription-polymerase chain reaction (RT-
PCR). In other brain areas, including the lateral hypothalamus, the arcuate nucleus, the 
olfactory bulb and the paraventricular nucleus, GLUT2 mRNA is merely detectable. 
Immunohistochemistry confirms the existence of GLUT2 in the above brain areas, with high 
immunoreactivity in the NTS-MNV and arcute nucleus. Further confirmation by Western 
Blot fails to show GLUT2 protein in the arcuate nucleus and NTS, suggesting the very low 
level of GLUT2 protein in these areas. Electronic microscope examination indicates that 
GLUT2 is expressed in the astrocytes but not neurons. Brant and colleagues (Brant, Jess et al. 
1993) show by Western Blot that GLUT2 is expressed at all regions of the brain including 
the hypothalamus; and the expression level is too low to be quantified. A more recent study 
reports GLUT2 protein in the tanycytes along the third ventricle in the hypothalamus (Garcia, 
Millan et al. 2003). Tanycytes are highly elongated ependymal cells, and there are four types, 
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α1, α2, β1, and β2. α1 and α2 tanycytes line the dorsal walls of the third ventricle and mainly 
project to the ventromedial nucleus of the hypothalamus. β1 tanycytes line the lower part of 
the third ventricle and may contact the arcuate nucleus. β2 tanycytes line the floor of the third 
ventricle and contact the median eminence. The presence of GLUT2 in the tanycytes 
indicates that GLUT2 may detect glucose concentration in the blood and the cerebrospinal 
fluid and send signals to neurons in the ventromedial nucleus and arcuate nucleus. Thus 
GLUT2 may play a role in the brain glucose sensing, like in the β cells. Taken together, 
GLUT2 is expressed in the brain at low levels and the localization of GLUT2 suggests that it 
may play a role in the brain glucose sensing. 
Wan and colleagues (Wan, Hulsey et al. 1998) show that ICV injection of antisense 
oligos against GLUT2 mRNA in rats causes significant suppression in food intake by the 
12th hour after injection, and remained suppressed at 24 h. The cumulative food intake is 
significantly lower in the antisense-injected rats. They also show that in antisense-treated 
rats, 2DG fails to stimulate feeding compared with vehicle control, whereas in missense 
treated rats, 2DG significantly increases food intake. Leloup and colleagues (Leloup, Orosco 
et al. 1998) injected antisense oligos to GLUT2 directly into arcuate nucleus twice daily for 
two days. After the first day injection, the rats administered antisense oligos have a 
significant body weight loss compared with missense and saline injected rats, which is not 
due to a decreased food intake, suggesting that GLUT2 may be involved in regulation of 
energy expenditure. Antisense treatment abolishes hyperinsulinemia induced by carotid 
artery injection of a small glucose load, indicating that GLUT2 may play a role in the brain 
glucose sensing. In summary, GLUT2 may be involved in the brain glucose sensing, 
regulation of food intake, and energy expenditure. 
 
 29
ATP Sensitive K (KATP) Channel 
In the Pancreas 
Like GLUT2 and GK, KATP channel is required for normal glucose sensing and 
insulin secretion of pancreatic β cells (Ashcroft and Gribble 1998). The β cells KATP channels 
consist of two subunits: a sulphonylurea receptor subunit (SUR1) and an inwardly rectifying 
K-channel subunit (Kir6.2). SUR1 is the regulatory subunit of KATP channels; and Kir6.2 is 
the pore-forming subunit. Sulphonylureas and diazoxide binding to SUR1 result in inhibition 
and activation of KATP channels. ATP probably binds to Kir6.2 and inhibits KATP channels; 
and MgADP binds to SUR1 and activates KATP channels. Both kir6.2 and SUR1 are 
important in the regulation of KATP channels activity and insulin secretion. 
In the Brain 
KATP channel components, Kir6.2 and SUR1, are widely expressed in the brain, 
including cortex, hippocampus, midbrain, hypothalamus, cerebellum and hindbrain 
(Karschin, Ecke et al. 1997; Dunn-Meynell, Rawson et al. 1998). Kir6.2 is primarily located 
in neurons, but not glial cells (Dunn-Meynell, Rawson et al. 1998). The widespread 
expression of KATP channels suggests that KATP channels may play a vital role in the brain 
function, such as neuroprotection and silencing of neurons in the presence of extreme 
hypoglycemia (Mobbs, Kow et al. 2001). Further, in situ hybridization shows that in the 
hypothalamus and hindbrain, expression of Kir6.2 mRNA and SUR1 mRNA is overlapped 
(Karschin, Ecke et al. 1997), Kir6.2 mRNA is colocalized with NPY mRNA in the arcuate 
nucleus in the hypothalamus (Dunn-Meynell, Rawson et al. 1998). Single neuron RT-PCR 
shows that Kir6.2 and SUR1 mRNA was coexpressed in the GABA neurons of ventromedial 
hypothalamus (VMH), Taken together, the pancreatic β cell KATP channel is widely 
expressed in the brain. 
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In addition to global neuroprotection in the presence of extreme hypoglycemia, the 
role of KATP channel in the whole body glucose homeostasis has been examined in the 
Kir6.2-deficient (Kir6.2-/-) mice. The Kir6.2-/- mice cannot increase glucagon secretion after 
systemic hypoglycemia induced by insulin injection, although glucagon secretion in response 
to low glucose (1 mM) in cultured islets from Kir6.2-/- mice is similar to control. The Kir6.2-/- 
mice cannot increase glucagon secretion in response to third ventricle injection of 2-
deoxyglucose, whereas the control mice can. The impaired counter-regulatory response to 
hypoglycemia and central glucoprivation suggests that central KATP channel play a role in the 
whole body glucose homeostasis (Miki, Liss et al. 2001). VMH neurons from Kir6.2-/- mice 
display a higher spontaneous activity at 2.5 mM glucose but do not increase firing when 
changed to 25 mM glucose, compared with control, implying that VMH neurons require 
Kir6.2-containing KATP channel for glucose sensing. Because VMH is involved in the 
glucagon secretion (Borg, During et al. 1994; Borg, Sherwin et al. 1995; Borg, Sherwin et al. 
1997), the abnormal glucose sensing of Kir6.2-/- VMH neurons results in the impaired 
glucagon response to hypoglycemia and glucoprivation.  
KATP channel in the hypothalamic neurons is affected by insulin and leptin 
(Spanswick, Smith et al. 1997; Spanswick, Smith et al. 2000). In the normal Sprague-Dawley 
rats and lean Zucker rats, both leptin and insulin cause hyperpolarization and decreased firing 
of hypothalamic neurons by activation of KATP channel, which effect is reversed by 
sulphonylurea tolbutamide. In contrast, leptin and insulin have no effect on the firing rate of 
hypothalamic neurons from obese Zucker rats, implying that KATP channel plays a role in the 
central action of leptin and insulin, and therefore is involved in the central regulation of 
energy homeostasis. In summary, KATP channel in the brain is involved in global 
neuroprotection, central glucose sensing and regulation of glucose and energy homeostasis. 
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GLP-1 and GLP-1 Receptor 
Function in Glycemic Control 
Peripherally, enteroendocrine cells in the small intestine secrete GLP-1. GLP-1 
receptors are G-protein coupled receptors; GLP-1 receptors have been localized on the 
membrane of pancreatic α and β cells. GLP-1 binds to GLP-1 receptor, activates Gs and 
adenylate cyclase (AC), increases cAMP levels and activates protein kinase A (PKA) and 
other downstream effectors, leading to insulin secretion. GLP-1 signaling not only stimulates 
glucose-dependent insulin secretion from β cells, but also activates insulin gene promoter 
and insulin transcription (Drucker 1998; Drucker 2001). GLP-1 and GLP-1 receptor play an 
important role in the regulation of insulin secretion and synthesis. 
The study with GLP-1 receptor mutant (GLP-1R-/-) mice demonstrates the importance 
of GLP-1 in glycemic control. GLP-1R-/- mice show increased fasting blood glucose, 
impaired glucose tolerance, irrespective of the route of glucose administration, and reduced 
insulin secretion 30 minutes after oral glucose challenge, compared with control (Scrocchi, 
Brown et al. 1996). Furthermore, GLP-1R-/- mice show normal fasting glucagon and 
suppression of glucagon after glucose challenge; a small but not significant decrease in 
fasting insulin mRNA in the islets, and normal glucose utilization in the whole body. Taken 
together, GLP-1 stimulation of insulin secretion plays an essential role in the GLP-1 effect on 
glycemic control (Scrocchi, Marshall et al. 1998). 
In the Brain 
Several studies have established the expression of GLP-1 and GLP-1R in the brain. 
GLP-1 mRNA expression is restricted to nucleus of the solitary tract (NTS) and the olfactory 
bulb. GLP-1R mRNA is detected in numerous brain regions including the hypothalamus and 
the hindbrain (Alvarez, Roncero et al. 1996; Merchenthaler, Lane et al. 1999). In situ 
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hybridization shows colocalization of GLP-1R and GLUT2 or GK mRNA in the ependymal 
cells along the third ventricle and the arcuate nucleus, median eminence and supraoptic 
nucleus (Navarro, Rodriquez de Fonseca et al. 1996).   
GLP-1 is a mediator of satiety in the brain (Navarro, Rodriquez de Fonseca et al. 
1996; Turton, O'Shea et al. 1996). Intracerebroventricular (ICV) injection of GLP-1 
significantly reduces dark-phase food intake and food intake in 24 h fasting rats, compared 
with ICV saline control. ICV injection of GLP-1R antagonist, exendin (9-39), reverses GLP-
1 inhibition on feeding. GLP-1 significantly attenuates and GLP-1R antagonist significantly 
potentiates NPY-induced feeding. ICV injection of GLP-1 induces c-fos expression in the 
paraventricular nucleus (PVN), and 80% of CRH neurons colocalize with c-fos expression. 
In addition, central GLP-1 also induces c-fos in the ventrolateral part of the arcuate nucleus 
(ARC), area postrema and nucleus of the solitary tract (AP/NTS) and amygdala (Turton, 
O'Shea et al. 1996; Larsen, Tang-Christensen et al. 1997). Altogether, central GLP-1 may 
exert its anorexic effect through activation of CRH neurons in the PVN, probably other 
anorexic neurons in other areas related to regulation of food intake. In contrast to the 
anorexic effect of acute administration of GLP-1 or GLP-1 receptor antagonist, GLP-1 
receptor mutation in transgenic mice does not affect body weight and food intake compared 
with wild type mice, suggesting that GLP-1 mediated satiety is dispensable and can be 
compensated by other satiety mediators (Scrocchi, Brown et al. 1996). In summary, GLP-1 is 
one of the mediators of satiety and GLP-1 exerts its anorexic effect directly in the brain. 
Summary 
The hypothalamus plays an important role in the central regulation of energy 
homeostasis (Schwartz, Woods et al. 2000). Recently, AMPK has been implicated as the 
energy sensor in the hypothalamus and plays a central role in the regulation of food intake 
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(Minokoshi, Alquier et al. 2004). Glucose sensing in the hypothalamus contributes to the 
regulation of both energy homeostasis and glucose homeostasis (Levin 2001;  Penicaud, 
Leloup et al. 2002). The detection of β cell glucose sensing components (GK, GLUT2, ATP-
sensitive K channel) in the hypothalamus has led to the hypothesis that hypothalamus uses a 
similar model as pancreatic β cells for glucose sensing (Schuit, Huypens et al. 2001). The β 
cell glucose sensor glucokinase has been proposed to be a likely glucose sensor in the 
hypothalamus (Dunn-Meynell, Routh et al. 2002). The evidence that GLUT2 is expressed in 
the brain, and blocking brain GLUT2 has affected energy homeostasis suggests a possible 
role of GLUT2 in the brain glucose sensing, leading to the hypothesis for this work. 
Hypotheses 
The hypothalamus and the AP/NTS area in the hindbrain are involved in glucose 
sensing and regulation of food intake (Ritter, Slusser et al. 1981; Penicaud, Pajot et al. 1990; 
Navarro, Rodriquez de Fonseca et al. 1996; Lynch, Tompkins et al. 2000; Schuit, Huypens et 
al. 2001). Peripherally, GLUT2 is one of the glucose sensors in the pancreatic beta cells and 
is required for glucose stimulated insulin secretion. GLUT2 has been found expressed in the 
hypothalamus and the hindbrain (Brant, Jess et al. 1993; Leloup, Arluison et al. 1994); 
GLUT2 has been localized in the astrocytes (Leloup, Arluison et al. 1994) and ependymal 
cells along the third cerebral ventricle (Garcia, Millan et al. 2003), and probably in the 
neurons as well (Penicaud, Leloup et al. 2002). GLUT2 mRNA in the hypothalamus and the 
hindbrain is decreased by refeeding in 24-h food restricted rats compared with ad libitum 
controls (Zhou, Roane et al. 2003); GLUT2 mRNA in the hindbrain in Zucker fatty rats is 
decreased compared with lean controls (Bogacka, Roane et al. 2004), indicates that brain 
GLUT2 may be regulated by energy and glycemic status. Antisense oligos blockade of brain 
GLUT2 results in suppressed food intake and abolished brain regulated insulin secretion 
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(Leloup, Orosco et al. 1998; Wan, Hulsey et al. 1998), suggesting that brain GLUT2 may be 
involved in the central glucose sensing. To date, the role of GLUT2 in the brain and the 
regulation of brain GLUT2 are not completely understood yet. 
Based on the role of GLUT2 in the pancreatic β cells, the presence of GLUT2 in the 
hypothalamus and hindbrain, it is proposed that brain GLUT2 is likely to play a role in the 
central glucose sensing. It is proposed that GLUT2 in the hypothalamus and hindbrain will 
be upregulated by low energy and low glucose status, which will be tested in long term 
underfed rats and in cultured brain tissue as well as in the GLUT2-expressing N1E-115 
neuroblastoma cell line. To investigate the role of brain GLUT2, GLUT2 will be 
overexpressed in the GT1-7 neuroblastoma cell line, and it is proposed that GLUT2 
overexpression in the cells will result in higher cellular energy status and lower AgRP 
mRNA expression, compared with control cells. Taken together, this dissertation will 
demonstrate the involvement of GLUT2 in brain glucose sensing and possibly regulation of 
food intake. 
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CHAPTER 3 
DISTRIBUTION OF GLUCOKINASE, GLUCOSE TRANSPORTER GLUT2, 
SULFONYLUREA RECEPTOR-1, GLUCAGON-LIKE PEPTIDE-1 RECEPTOR 
AND NEUROPEPTIDE Y MESSENGER RNAS IN RAT BRAIN BY 
QUANTITATIVE REAL TIME RT-PCR1
 
Introduction 
GK, GLUT2, SUR1, GLP-1R and NPY have been identified in a number of brain 
areas (Gehlert, Chronwall et al. 1987; Morris 1989; Leloup, Arluison et al. 1994; Navarro, 
Rodriquez de Fonseca et al. 1996; Karschin, Ecke et al. 1997; Merchenthaler, Lane et al. 
1999; Lynch, Tompkins et al. 2000; Dunn-Meynell, Routh et al. 2002). GK has been 
proposed as a mediator of glucose sensing in the brain (Schuit, Huypens et al. 2001; Dunn-
Meynell, Routh et al. 2002). GLUT2 has been proposed to play a role in central regulation of 
food intake (Wan, Hulsey et al. 1998) or glucose sensing (Leloup, Orosco et al. 1998). SUR1 
may be important in central glucose sensing mechanisms (Lee, Dixon et al. 1999). GLP-1R 
and NPY have been associated with central inhibition and stimulation of food intake, 
respectively (Navarro, Rodriquez de Fonseca et al. 1996; Turton, O'Shea et al. 1996; 
Schwartz, Woods et al. 2000). GLP-1R mRNA is colocalized with GK or GLUT2 in the 
hypothalamus (Navarro, Rodriquez de Fonseca et al. 1996), NPY mRNA is colocalized with 
GK in the arcuate nucleus (ARC) (Lynch, Tompkins et al. 2000), implying that the regulation 
of GLP-1R or NPY activity may be influenced by glucose sensing processes. In the present 
study, the mRNA expression of GK, GLUT2, SUR1, GLP-1R and NPY in ten brain areas 
from individual rats is quantified using real time RT-PCR. Such information has not been 
previously reported and could be valuable as an initial step to understanding the central 
functions of these molecules. 
                                                 
1 Reprinted by permission of Molecular Brain Research 113 (2003) 139-142. 
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Materials and Methods 
Materials and Reagents 
 RNA extraction kit was obtained from Stratagene (La Jolla, CA). Taqman Primers 
and probes for GLUT2, AgRP and cyclophilin were obtained from Biosearch Technologies 
(Novato, CA). Real time RT-PCR reagents including MuLV reverse transcriptase, RNAse 
inhibitor and PCR reagent were obtained from Applied Biosystems (Branchburg, NJ). 
Brain Micropunch and RNA Isolation 
Four male S5B rats, two months old, were used in this study. Coronal brain sections 
were prepared at 300 um using a cryostat. In the hindbrain, sections were collected with three 
rostral to and two caudal to bregma –13.30 mm where the central canal disappears and the 
fourth ventricle appears. In the hypothalamus, seven sections were collected rostral to 
bregma –3.30 mm where the medial eminence appears (Paxinos and Waston 1998). Nucleus 
of the solitary tract (NTS), area postrema (AP), hypoglossal nucleus (12), inferior olive (IO), 
lateral reticular nucleus (LRt), ARC, ventromedial nucleus (VMN), paraventricular nucleus 
(PVN) and lateral hypothalamic area (LH) were removed by micropunch (Palkovits and 
Brownstein 1988). Care was taken not to include the ependymal cells around the third 
ventricle. Cortex samples were collected from the same sections containing ARC as a 
control. Total RNA from each area of each rat was isolated following the manual of RNA 
extraction kit, and RNA quantity was determined by OD260. 
Real Time RT-PCR 
Primers and Taqman probes (Table 1) for cyclophilin, GK, GLUT2, SUR1, GLP-1R, 
and NPY were synthesized by Biosearch Technologies. Cyclophilin was used as an internal 
control. Real time RT-PCR was performed on an ABI PRISM 7700 sequence detector. The 
reaction mixture contained: 10 ng RNA, PCR buffer, 5.5 mM MgCl2, dATP, dCTP, dTTP  
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Table 1. Primer and probe sequences for real-time RT-PCR. Cyc, cyclophilin; GK, 
glucokinase; GLUT2, glucose transporter GLUT2; SUR1, sulfonylurea receptor-1; GLP-1R, 
glucagon-like peptide-1 receptor; NPY, neuropeptide Y; F, forward primer; R, reverse 
primer; P, TaqMan probe. 
 
 
 
Name Sequence (5’-3’) Genbank 
Cyc F: CCCACCGTGTTCTTCGACAT                                       
R:  TGCAAACAGCTCGAAGCAGA 
P: CAAGGGCTCGCCATCAGCCG 
M19533 
GK F: CAAGCTGCACCCGAGCTT                                            
R: TGATTCGATGAAGGTGATTTCG                                 
P: TCAGCCTGCGCACACTGGCG 
M25807 
Glut2 F: GTCCAGAAAGCCCCAGATACC                                   
R: TGCCCCTTAGTCTTTTCAAGCT                                   
P: TTGCCCTGACTTCCTCTTCCAAATTTAGGTAA  
NM_012879 
SUR1 F: CACATTCACCACAGCACCTG 
R: CCAGCTGGCATGTATAAGTG 
P: CCCGTCAGACAGGATACCCTCAG 
NM_013039 
GLP-1R F: CTGCATCGTGATAGCCAAGCT                                   
R: GGACTTCGCGAGTCTGCATT 
P: AGGCTAATCTCATGTGTAAGACC 
S75952 
NPY F: TCTGCCTGTCCCACCAATG                                          
R: CAACGACAACAAGGGAAATGG  
P: CCACCACCAGGCTGGATTCCGA 
M20373 
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and dGTP each 0.3 mM, 500 nM forward primers, 500 nM reverse primers, 200 nm Taqman 
probes, 5 U RNAse inhibitor, 12.5 U MuLV Reverse Transcriptase, 1.5 U AmpliTaq Gold 
DNA polymerase (Applied Biosystems). The reaction condition was: 48°C for 30 min for 
RT; one cycle of 95°C for 10 min plus 40 cycles of 95°C for 15 sec and 60°C for 1 min for 
PCR. PCR products were sequenced. The relative mRNA level of each gene was expressed 
as its ratio to cyclophilin. Data are reported as means ± SE. 
Results 
Sequencing of PCR products confirmed the correct amplification of cyclophilin, GK, 
GLUT2, SUR1, GLP-1R and NPY mRNA. GK mRNA was expressed at high levels in ARC 
and VMN, moderate in PVN, LH and IO, low in NTS, AP, LRt, very low in 12 and not 
detected in cortex. GLUT2 mRNA was expressed at high levels in 12, moderate to low in 
NTS, AP, IO, LRt, ARC, VMN, PVN, LH, and very low in cortex. SUR1 mRNA was 
expressed at moderate to low levels across the hindbrain and the hypothalamus, and at 
moderate levels in cortex. GLP-1R mRNA was expressed at low levels in the hypothalamus 
and the hindbrain, with relatively higher expression in AP and ARC, and not detectable in 
cortex. NPY mRNA expression was highest in ARC, moderate in NTS, AP, IO, LRt and 
VMN, low in PVN and LH, and very low in 12. Moderate levels of NPY mRNA were 
detected in cortex (Figure 1). 
Discussion   
In the current study, we have demonstrated mRNA distribution of GK, GLUT2, 
SUR1, GLP-1R and NPY in rat brain. Real time RT-PCR, together with micropunch, 
provides a sensitive and reliable method for examination of mRNA expression in specific 
brain areas. Our results are consistent with previous in situ hybridization and conventional 
RT-PCR studies 
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Figure 1. Glucokinase (GK), glucose transporter GLUT2, sulfonylurea receptor-1 (SUR1), 
glucagon-like peptide-1 receptor (GLP-1R) and neuropeptide Y (NPY) mRNA expression in 
specific areas in S5B rat brain. The relative amount of mRNA was expressed as ratio to 
cyclophilin (cyc). NTS, nucleus of the solitary tract; AP, area postrema; 12, hypoglossal 
nucleus; IO, inferior olive; LRt, lateral reticular nucleus; ARC, arcuate nucleus; VMN, 
ventromedial nucleus; PVN, paraventricular nucleus; LH, lateral hypothalamic area. Data are 
reported as means ± SE. 
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(Gehlert, Chronwall et al. 1987; Morris 1989; Leloup, Arluison et al. 1994; Navarro, 
Rodriquez de Fonseca et al. 1996; Karschin, Ecke et al. 1997; Merchenthaler, Lane et al. 
1999; Lynch, Tompkins et al. 2000; Dunn-Meynell, Routh et al. 2002). GK has been 
proposed to mediate glucose sensing in the brain (Dunn-Meynell, Routh et al. 2002); GLUT2 
has been proposed to play a role in central regulation of food intake (Wan, Hulsey et al. 
1998) or glucose sensing (Leloup, Orosco et al. 1998). The presence of GK and GLUT2 
mRNA in ARC, VMN, PVN, LH, NTS and AP indicates that GK and GLUT2 may function 
in these areas that are known to be involved in central glucose sensing and regulation of food 
intake (Contreras, Fox et al. 1982; Bird, Cardone et al. 1983; Ritter, Dinh et al. 2000; Schuit, 
Huypens et al. 2001; Dunn-Meynell, Routh et al. 2002). IO, LRt and 12 have not been related 
to glucose sensing and the function of GK and GLUT2 mRNA in these nuclei is unknown. It 
is interesting to note that GLUT2 mRNA distribution in the brain is not parallel to GK. 
GLUT2 mRNA was lower than GK in ARC, VMN, PVN, LH and IO, similar to GK in AP, 
and higher than GK in NTS, 12 and LRt. GLUT2 has only been identified in astrocytes 
(Leloup, Arluison et al. 1994), and GK appears to be primarily expressed in neurons (Lynch, 
Tompkins et al. 2000; Dunn-Meynell, Routh et al. 2002), which might explain their non-
parallel expression. On the other hand, these brain areas might assume different roles in 
terms of glucose sensing, as is seen in pancreatic α and β cells, where α cells only express 
GK but not GLUT2, whereas β cells express both (Heimberg, De Vos et al. 1995; Heimberg, 
De Vos et al. 1996). SUR1 is the regulatory subunit of ATP-sensitive K+ (KATP) channels; the 
widespread expression of SUR1 mRNA is in agreement with the two proposed roles of KATP 
channels in the brain: neuroprotection and glucose sensing when co-expressed with other 
glucose sensing mediators (Lee, Dixon et al. 1999; Mobbs, Kow et al. 2001). The relatively 
high expression of GLP-1R mRNA in ARC and AP suggests that ARC and AP may be the 
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major sites of GLP-1 activity. The high levels of NPY mRNA in ARC is consistent with 
previous reports that ARC is the predominant nucleus for NPY synthesis (Schwartz, Woods 
et al. 2000). Whether NPY mRNA in IO and LRt is related to food intake regulation or other 
functions as a neurotransmitter is yet to be elucidated. 
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CHAPTER 4 
THE ROLE OF GLUCOSE TRANSPORTER 2 IN BRAIN GLUCOSE SENSING 
 
Introduction 
Glucose transporter 2 (GLUT2) is a high Km and low affinity facilitative glucose 
transporter. GLUT2 has been identified in both the peripheral tissue and the brain. In the 
peripheral tissue, GLUT2 has been localized in liver, pancreatic β cell, intestine and kidney 
(Thorens, Sarkar et al. 1988). In the liver, GLUT2 is the major glucose transporter that is 
responsible to transport glucose in and out of hepatocytes to maintain blood glucose 
homeostasis (Thorens, Sarkar et al. 1988). Liver GLUT2 is decreased by fasting and 
increased by refeeding (Thorens, Flier et al. 1990). Liver GLUT2 is up regulated by glucose, 
which requires glucose metabolism (Asano, Katagiri et al. 1992; Rencurel, Waeber et al. 
1996). In the pancreatic β cells, GLUT2 has been proposed as a glucose sensor and GLUT2 
is required for glucose stimulated insulin secretion (Guillam, Hummler et al. 1997; Guillam, 
Dupraz et al. 2000). β cell GLUT2 is decreased during hypoglycemia and increased during 
hyperglycemia (Thorens, Deriaz et al. 1996). As in the liver, β cell GLUT2 is upregulated by 
glucose, which also requires glucose metabolism (Ferrer, Gomis et al. 1993).  
In the brain, GLUT2 has been found to be widely expressed at low levels (Brant, Jess 
et al. 1993; Leloup, Arluison et al. 1994). Compared with the cortex, GLUT2 expression in 
specific areas in the hypothalamus and hindbrain are relatively higher (Leloup, Arluison et al. 
1994; Li, Xi et al. 2003). In the brain, GLUT2 has been localized in the astrocytes (Leloup, 
Arluison et al. 1994) and ependymal cells along the third cerebral ventricle (Garcia, Millan et 
al. 2003); and GLUT2 may be expressed in the neurons as well (Penicaud, Leloup et al. 
2002). Antisense oligos blocking of brain GLUT2 resulted in suppressed food intake, 
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increased energy expenditure and abolished brain regulated insulin secretion (Leloup, Orosco 
et al. 1998; Wan, Hulsey et al. 1998), suggesting that brain GLUT2 might be involved in the 
central glucose sensing. GLUT2 mRNA in the hypothalamus and the hindbrain is decreased 
by refeeding in 24 hour food restricted rats compared with ad libitum controls (Zhou, Roane 
et al. 2003); GLUT2 mRNA in the hindbrain in Zucker fatty rats is decreased compared with 
lean controls (Bogacka, Roane et al. 2004), indicates that brain GLUT2 may be regulated by 
energy and glycemic status. To date, the role of GLUT2 in the brain and the regulation of 
brain GLUT2 are not completely understood yet. 
In our previous report, we have used N1E-115 and GT1-7 neuroblastoma cell lines as 
in vitro model to investigate the effect of glucose on cellular ATP levels and orexigenic 
neuropeptide AgRP mRNA expression (Lee, Li et al. 2005). In this study, we investigated the 
regulation of brain GLUT2 by energy status in the two-week underfed rats; we applied 
various glucose to rat AP/NTS tissue culture and GLUT2-expressing N1E-115 cell culture to 
understand the role of glucose in the regulation of brain GLUT2. To illustrate the function of 
GLUT2 in the brain, we overexpressed rat liver GLUT2 in the GT1-7 cells; and examined 
cellular ATP and AgRP mRNA response to various glucose and 2DG in the GLUT2 
overexpressed GT1-7 cells and control cells. 
Materials and Methods 
Materials and Reagents 
 For glucose measurement: glucose reagent (Sigma, St. Louis, MO). For tissue culture, 
cell culture and treatments: Dulbecco’s Modified Eagle’s Medium (DMEM), fetal bovine 
serum (FBS), penicillin-streptomycin and trypsin-EDTA (Invitrogen, Carlsbad, CA), glucose 
and 2-deoxyglucose (2DG) (Sigma, St. Louis, MO). For RNA isolation from micropunched 
brain tissue: RNA extraction kit (Stratagene, La Jolla, CA). For RNA isolation from tissue 
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and cell culture: Trizol (Invitrogen, Carlsbad, California), chloroform (Fisher Scientific, Fair 
Lawn, NJ). isoproponal and formamide (Sigma, St. Louis, MO). For GLUT2 cloning: Access 
RT-PCR kit, restriction enzyme KpnI, NotI, BamHI and HindIII (Promega, Madison, WI), 
PCR purification kit and plasmid purification kit (Qiagen, Santa Clarita, CA), TA cloning kit 
and pcDNA3.1 vector (Invitrogen, Carlsbad, CA). For transfection and selection: 
LipofectAMINE, OptiMEM medium and Geneticin G418 (Invitrogen, Carlsbad, CA). For 
Western Blot: protease inhibitor (Sigma, St. Louis, MO), rabbit anti-GLUT2 antibody 
(Biogenensis, Poole, England), HRP-conjugated donkey anti-rabbit secondary antibody 
(Jackson Immunoresearch, West Grove, PA), and chemiluminent reagent (Periece, Rockford, 
IL). For ATP measurement: ATP Assay Kit (Sigma, St. Louis, MO). For real time RT-PCR: 
Taqman Primers and probes for GLUT2, AgRP and cyclophilin (Biosearch Technologies, 
Novato, CA), real time RT-PCR reagents including MuLV reverse transcriptase, RNAse 
inhibitor and PCR reagent (Applied Biosystems, Branchburg, NJ).  
Animal 
Male Sprague-Dawley rats (Harlan, Indianapolis IN), were housed in hanging cages 
in a temperature (22 ± 2°C) and humidity (40-50%) controlled room, with a 12-h light:dark 
cycle. Rats had free access to tap water and regular rat chow (Lab Diet, rat chow 5001) 
unless otherwise specified. Animal care and use was carried out in accordance with the 
guidelines of the Institutional Animal Care and Use Committee at the Louisiana State 
University and Pennington Biomedical Research Center. 
Male Sprague-Dawley rats, weighing about 300 g, were fed powder rat chow (Lab 
Diet, rat chow 5001). The animals were randomly assigned to two groups (n = 8 each group): 
ad libitum fed or given 50% of ad libitum food intake for two weeks. Body weight was 
recorded daily in the morning. At the end of the study, the animals were euthanized by 
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decapitation. For serum sample, trunk blood was collected, placed in ice, allowed to clot, 
centrifuged at 6000 rpm for 20 min at 4°C, serum was collected and stored at -70 °C. For 
brain, whole brain was excised and placed on dry ice, and later stored at -70 °C. 
Serum Glucose Measurement 
Serum glucose was measured using glucose reagent according to the manufacturer’s 
instructions. To make the standard curve for glucose, 60 mg, 120 mg, 180 mg, 240 mg and 
300 mg of glucose in 3 ul of water was mixed with 300 ul of glucose reagent, incubated at 
37°C for 3 min, and OD340 was determined. The OD340 values were regressed on the 
glucose concentration to obtain the glucose standard curve. For sample measurement, 3 ul of 
sample serum was mixed with glucose reagent, incubated at 37°C for 3 min, and OD340 was 
determined. The glucose concentration in each sample was calculated based on the standard 
curve, expressed as mmol/l (mM). 
Brain Micropunch and RNA Isolation 
Coronal brain sections were prepared at 300 um using a cryostat. In the hindbrain, 
bregma –13.30 mm where the central canal disappears and the fourth ventricle appears was 
used as a recognition marker; and three sections rostral to plus two sections caudal to bregma 
–13.30 mm were collected. In the hypothalamus, seven sections were collected rostral to 
bregma –3.30 mm where the medial eminence appears (Paxinos and Waston 1998). The 
sections were thaw-mounted on a glass slide, and stored on dry ice. Nucleus of the solitary 
tract (NTS), area postrema (AP), arcuate nucleus (ARC), ventromedial nucleus (VMN), 
paraventricular nucleus (PVN) and lateral hypothalamic area (LH) were removed by 
micropunch (Palkovits and Brownstein 1988). Care was taken not to include the ependymal 
cells along the third ventricle. The inner diameter of the punch was 0.52 mm. After each 
punch, the tissue was immediately put into 100 ul of ice-cold 2-mecaptoethanol-lysis buffer 
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and vortex vigorously for 20 to 30 sec until homogenized. Two tubes of lysis buffer were 
used alternatively for one rat and always kept on ice during the interim of vortex to prevent 
overheating. Equal volumes of 70% ethanol were added to the tissue lysate and mixed 
thoroughly by vortexing for 5 sec. The ethanol-lysate mixture was stored at -70°C until we 
completed the punching of all the samples before proceeding with RNA isolation. 
Total RNA from micro-punched tissue was isolated from each individual rat 
following the manual of the RNA extraction kit. Two ethanol-lysate mixtures from one rat 
were vortexed again for 5 sec, combined and transferred to a RNA-binding cup that was 
placed on a 2-ml collection tube, and centrifuged for 1 min at 18,000 x g at 4°C. The 
following spin also occurred at 18,000 x g at 4°C. The filtrate was discarded, and 600 ul of 
low-salt wash buffer was added to the cup, which was then spun for 1 min. The filtrate was 
discarded and the cup was spun for another 2 min to dry the fiber matrix. Next, 30 ul of 
RNase-free DNase I solution was applied directly onto the fiber matrix inside the cup, which 
was then incubated in a 37°C water bath for 15 min. The RNA was washed sequentially with 
500 ul of high-salt, 600 ul and 300 ul of low-salt wash buffer; after each wash the cup was 
spun for 1 min. Following the final wash the cup was spun for 2 min to dry the fiber matrix. 
The cup was transferred to a 1.5-ml collection tube, and 40 ul of elution buffer was added 
directly onto the fiber matrix. After a 2-min incubation at room temperature, the cup was 
spun for 1 min. The eluted RNA was mixed with 20 ul of formamide and stored at -70°C. For 
RNA quantification, 10 ul of sample RNA was diluted into 90 ul of H2O, and the optical 
density (OD) 260 and OD280 was measured using a UV spectrophotometer. GLUT2 mRNA 
expression was determined by real time RT-PCR. For each brain area, GLUT2 mRNA levels 
were normalized by cyclophilin and reported as percentages of values, considering the values 
obtained from the ad libitum fed rats in the respective area as 100 percentages. 
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Ex Vivo Culture 
 Male adult Sprague Dawley rats, weighing about 400 g, were euthanized by 
decapitation. Fresh AP/NTS area in the hindbrain were excised (from bregma –14.60 mm to -
13.00 mm) (Paxinos and Waston 1998) and immediately cultured in the DMEM containing 
2% FBS, and 1 mM or 2.5 mM glucose (n = 11 for each treatment) at 37°C for 3 h. The 
tissue was homogenized in 500 ul of Trizol, total RNA was isolated following the 
manufacturer’s instructions. The homogenate-chloroform was mixed with 100 ul of 
chloroform and centrifuged at 18,000 x g at 4°C for 15 min for phase separation. For RNA 
precipitation, 150 ul of aqueous supernatant was transferred to a 1.5 ml-Eppendorf tube, 
mixed with 200 ul of isoproponal, and incubated at room temperature for 15 min, followed 
by centrifuge at 18,000 x g at 4°C for 15 min. The precipitated RNA pellet was washed by 
300 ul of 75% ethanol, centrifuged at 18,000 x g at 4°C for 5 min, the ethanol was removed, 
and the RNA pellet was allowed to dry in air for 5 to 10 min. The RNA pellet was dissolved 
in 40 ul of RNase-free H2O containing 50% formamide and stored at -70°C. GLUT2 mRNA 
expression was determined by real time RT-PCR. GLUT2 levels were normalized by 
cyclophilin and reported as percentages of values, considering the values obtained at 2.5 mM 
glucose as 100 percentages.  
In Vitro Culture and Treatment of N1E-115 Cells 
N1E-115 mouse neuroblastoma cell line was obtained from ATCC (Manassas, VA). 
The cells were grown in DMEM containing 25 mM glucose, 10% fetal bovine serum (FBS), 
50 units of penicillin and 50 µg/ml streptomycin at 37°C in 5% CO2 unless otherwise 
specified. For glucose treatment, N1E-115 cells were grown to 90% confluence, and then 
incubated in DMEM containing 2% FBS and various levels (1, 2.5, 5 mM) of glucose for 16 
h. The treatment was repeated three times with duplicate each time. The cells were 
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homogenized in 500 ul of Trizol, total RNA was isolated as stated in ex vivo culture, and 
dissolved in 40 ul of RNase-free H2O containing 50% formamide. GLUT2 mRNA 
expression was determined by real time RT-PCR. GLUT2 levels were normalized by 
cyclophilin and reported as percentages of values, considering the values obtained at 2.5 mM 
glucose as 100 percentages. 
Real Time RT-PCR for GLUT2
Real time RT-PCR was used to determine GLUT2 mRNA levels in the samples; 
cyclophilin (cyc) was used as an internal control to normalize the RNA levels in each sample. 
The sequences of the primers and probes for rat cyclophilin and GLUT2, mouse cyclophilin 
and GLUT2 were listed in Table 2. Real time RT-PCR reaction mixture was 50 ul of total 
volume, including 10 ng of sample RNA, 1 X PCR buffer, 5.5 mM MgCl2, dATP, dCTP, 
dUTP and dGTP each 0.3 mM, 500 nM forward primers, 500 nM reverse primers, 200 nM 
Taqman probes, 5 U RNase inhibitor, 12.5 U MuLV reverse transcriptase, 1.5 U AmpliTaq 
Gold DNA polymerase and RNase-free H2O. Each sample was tested in duplicate. Reverse 
transcription was carried out at 48°C for 30 min.  PCR was carried out at 95°C for 10 min for 
one cycle, followed by 40 cycles of 95°C for 15 sec and 60oC for 1 min. Data was output as 
Ct number (cycle threshold number) and the data within the linear region of the amplification 
curve are analyzed according to ABI's user bulletin #2. The relative amounts of GLUT2 
mRNA were calculated using ∆∆Ct method and normalized by cyclophilin. 
Mammalian Cell Expressing Vector pcDNA3.1-GLUT2
 Full-length rat GLUT2 (Genbank NM_012879) cDNA was obtained by RT-PCR 
using Access RT-PCR kit from Promega. The primers used to amplify GLUT2 were: forward 
5’TCCGCACACAACATGTCAGAA3’, reverse 5’TCCTCACACAGTCTCTGATG3’. The 
RT-PCR reaction was performed in a volume of 50 ul, containing (in final concentration) 1 x 
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Table 2. The sequences of primers and probes for real time RT-PCR. F: forward primer, R: 
reverse primer, P: Taqman probe, cyc: cyclophilin, GLUT2, glucose transporter 2, AgRP: 
agouti-related peptide. 
 
 
 
 
Gene Sequence Genbank 
Rat cyc F: 5’CCCACCGTGTTCTTCGACAT3’ 
R: 5’TGCAAACAGCTCGAAGCAGA3’ 
P: 5’CAAGGGCTCGCCATCAGCCG3’ 
M19533 
Rat 
GLUT2 
F: 5’GTCCAGAAAGCCCCAGATACC3’ 
R: 5’TGCCCCTTAGTCTTTTCAAGCT3’ 
P: 5’TTGCCCTGACTTCCTCTTCCAAATTTAGGTAA3’ 
NM_012879 
Mouse 
cyc 
F: 5’GGCCGATGACGAGCCC3’ 
R: 5’TGTCTTTGGAACTTTGTCTGCAA3’ 
P: 5’TGGGCCGCGTCTCCTTCGA3’ 
NM_008907 
Mouse 
GLUT2 
F: 5’GACAAACTTGGAAGGATCAAAG3’ 
R: 5’AATTTGGAACATCCCATCAAGAG3’ 
P: 5’CTGCAAACAGCCTCTCATTGACTGGAGC3’ 
NM_031197 
Mouse 
AgRP 
F: 5’GTACCGCCACGAACCTCTGT3’ 
R: 5’TCCCCTGCCTTTCCCAAA3’ 
P: 5’TCGCACCTAGCCAATGGATGTT3’ 
NM_007427 
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 AMV/Tfl buffer, 1 mM MgSO4, 0.2 mM dATP, dCTP, dDTP and dGTP each, 1 uM 
forward and reverse primer each, 5 units of AMV reverse transcriptase, 5 units of Tfl DNA 
polymerase, and 0.5 ug of liver RNA as template. RT-PCR reaction was carried out at 45°C 
for 45 min; 94°C for 2 min; 39 cycles of 94°C for 30 sec, 58°C for 1 min, and 68°C for 2 min 
and 30 sec; and final extension at 68°C for 10 min. PCR products were detected by 1% 
agarose gel. The ~1.6 kb PCR band of GLUT2 was excised from the gel, purified by PCR 
purification kit, and cloned into pCR2.1 vector (TA cloning kit). The insertion of GLUT2 
gene in pCR2.1 vector was verified by HindIII and BamHI restriction enzyme digestion, and 
further sequenced to ensure correct open reading frame of GLUT2. To transfer the GLUT2 
gene from pCR2.1 vector to mammalian cell expressing pcDNA3.1 vector, the pcDNA3.1 
and pCR2.1-GLUT2 vector were subject to KpnI / NotI restriction enzyme digestion, which 
was verified by 1% agarose gel. The ~1.6 kb GLUT2 cDNA and ~5.4 kb linear pcDNA3.1 
were excised from the agarose gel, purified by PCR purification kit, and subject to ligation. 
The GLUT2 insertion into pcDNA3.1 was verified by EcoRI enzyme digestion. The 
pcDNA3.1 vector with correct GLUT2 insert, referred to as pcDNA3.1-GLUT2, was 
amplified, purified by plasmid purification kit, quantified by OD260, and used for in vitro 
transfection. 
In Vitro Transfection of GT1-7 Cells with pcDNA3.1-GLUT2 Vector 
GT1-7 mouse neuroblastoma cell line was a generous gift from Dr. Pamela Mellon 
(University of California, San Diego). The cells were grown in DMEM containing 25 mM 
glucose, 10% FBS, 50 units of penicillin and 50 µg/ml streptomycin at 37°C in 5% CO2. On 
the day before transfection, the cell culture medium was changed to DMEM containing 25 
mM glucose and 10% FBS but without antibiotics. On the day of transfection, GT1-7 cells 
were about 50-70% confluence. For one well of cells grown in a 6-well plate, 4 ug of 
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pcDNA3.1-GLUT2 vector and 10 ul of transfection reagent LipofectAMINE were diluted 
with 250 ul of OptiMEM medium each. The diluted DNA and LipofectAMINE were mixed 
gently and the mixture was incubated at room temperature for 20 min. GT1-7 cells were 
incubated with DNA-LipofectAMINE mixture for 4 h to allow LipofectAMINE mediated 
DNA entry into the cells, then fresh DMEM containing 25 mM glucose and 10% FBS was 
added. The next day, the cells were split at 1:10 ratio, and subject to selection with 500 ug/ml 
G418 for 10 –14 days. The pcDNA3.1 vector contain G418-resistant gene; by G418 
selection, only cells with the vector incorporated into the genome that were able to express 
G418 resistant gene could survive. In the end, G418-resistant clones of cells were pooled and 
amplified for subsequent treatments. In parallel, GT1-7 transfected with pcDNA3.1 empty 
vector were obtained to serve as controls in the following experiments. In the following 
experiments, GT1-7 cells transfected with pcDNA3.1-GLUT2 vector will be referred to as 
GT1-7GLUT2, and GT1-7 cells transfected with pcDNA3.1 empty vector will be referred to as 
GT1-7pcDNA. The stably transfected cells were grown in DMEM containing 25 mM glucose, 
10% FBS, 50 units of penicillin, 50 µg/ml streptomycin and 250 ug/ml G418. 
Western Blot of GLUT2
The overexpression of GLUT2 in GT1-7 cells was verified by Western Blot. The cells were 
homogenized in lysis buffer containing 100 mM Tris-HCl, pH 6.8, 0.1% SDS and 1% protease 
inhibitor. The cell lysate was centrifuged at 10,000 rpm for 10 min at 4°C, and supernatant was 
collected for protein detection. The protein was separated on an 8% SDS-polyacrylamyl gel and 
transferred to PVDF membrane. Non-specific bindings were blocked with 5% non-fat dry milk in 
TBST buffer (10 mM Tris-HCl, pH at 7.4, 150 mM NaCl, 0.5% Tween-20) for 1 h. The membrane 
was incubated with polyclonal rabbit anti-GLUT2 primary antibodies for 3 h (1:1000 dilution), and 
washed five times for 10 min each. The membrane was further incubated with horseradish 
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peroxidase (HRP) conjugated secondary antibody (1:10,000 dilution) for 1 h, and washed five times 
for 10 min each. The antibodies were diluted in 5% non-fat dry milk in TBST buffer, the membrane 
was washed in TBST buffer, and the incubation and washes were carried out at room temperature. 
The protein on the membrane was detected by chemiluminent reagent. 
Treatments of GT1-7GLUT2 and GT1-7pcDNA Cells 
 To examine AgRP mRNA response to glucose, GT1-7GLUT2 and GT1-7pcDNA cells 
were cultured in DMEM containing 2% FBS and various levels of glucose (1, 2.5, 5, 10, 25 
mM) for 16 or 24 h. To examine AgRP mRNA response to 2DG, GT1-7GLUT2 and GT1-
7pcDNA cells were cultured in DMEM containing 2% FBS, 2.5 mM glucose with or without 5 
mM 2DG for 24 h. Total RNA was isolated using Trizol, the mRNA expression of AgRP was 
determined by real time RT-PCR (methods were described above.). Primers and probes for 
AgRP were listed in Table 2. Data were expressed as ratio to cyclophilin, and were reported 
as percentages of values. For glucose dose response, we considered the values obtained at 1 
mM glucose of each group as 100 percentages, for response to 2DG, we considered the 
values obtained at 2.5 mM glucose without 2DG treatment of each group as 100 percentages.  
ATP Measurement 
Cellular ATP concentration (n = 3-6) was measured using the ATP Assay Kit according 
to the manufacturer's instructions. 300 ul of ATP lysis buffer were used for Cells cultured in 
24-well plate to release ATP; 50 ul of cell lysate were used for reaction with an equal amount 
of diluted ATP assay mix for ATP measurement. Data were reported as percentages of 
values, considering the values obtained at 1 or 2.5 mM glucose without 2DG as 100 
percentages for glucose dose response or response to 2DG experiment, respectively.  
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Data Analysis 
 Data were presented as mean ± S.E.M. For underfeeding and ex vivo studies, 
differences between the means were assessed by Student’s t-test. For in vitro study, 
differences between the means were assessed by Student’s t-test or one-way analysis of 
variance (ANOVA) and Tukey’s test. The significance level was set at p < 0.05. 
Results 
Two-Week Underfeeding Study 
At the end of two-week feeding, the body weight gain was - 65.3 ± 1.8 g for the 
underfed rats, and 37.9 ± 4.4 g for the ad libitum fed rats (Figure 2). The body weight gain 
was significantly different between the underfed and ad libitum fed rats (p < 0.0001, t-test). 
The serum glucose levels were 6.47 ± 0.21 mM for the underfed rats, and 6.02 ± 0.08 mM 
for the ad libitum fed rats. The serum glucose levels were not significantly different between 
the two groups of rats. 
Relative GLUT2 mRNA expression in the AP, NTS, ARC, VMN, PVN and LH was 
determined by real time RT-PCR; in each area, GLUT2 mRNA levels in the ad libitum fed 
rats were considered as 100 percentages (Figure 3). GLUT2 mRNA was significantly 
increased in the AP in two-week underfed rats, compared with ad libitum fed rats (p < 0.05, 
t-test). In the hypothalamic arcuate nucleus, GLUT2 mRNA was slightly increased in 
underfed rats but did not reach statistical significance. In other hypothalamic and hindbrain 
areas examined, GLUT2 mRNA was not different between the underfed rats and ad libitum 
fed rats. 
 Ex Vivo Culture 
The AP/NTS area was excised from the rat brain, and cultured in 1 or 2.5 mM 
glucose at 37˚C for 3 h. As shown in Figure 4, the GLUT2 mRNA had a significant 25% 
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Figure 2. Body weight gain (g) in the two-week 50% underfed rats and ad libitum fed rats. 
The body weight gain was significantly different between underfed rats and ad libitum fed 
rats (p < 0.0001). 
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 increase in AP/NTS tissue cultured in 1 mM glucose compared with those cultured in 2.5 
mM glucose (p = 0.03, t-test). 
In Vitro Cell Culture 
N1E-115 cells were grown in DMEM containing 25 mM glucose and 10% FBS till 
90% confluence, then switched to DMEM containing 2% FBS and 1, 2.5 or 5 mM glucose 
for 16 h. As shown in Figure 5, in N1E-115 cells, GLUT2 mRNA was decreased by glucose 
(p = 0.014, One-way ANOVA). GLUT2 mRNA levels were significantly lower when N1E-
115 cells were incubated with 5 mM glucose compared with 1 mM glucose (p < 0.05, 
Tukey’s test).  
Overexpression of GLUT2 in GT1-7 Cells 
 PCR2.1-GLUT2 vector was sequenced and confirmed to contain the correct in-frame 
GLUT2 gene as described in Genbank. After transfection of pcDNA3.1-GLUT2 or 
pcDNA3.1 vector into GT1-7 cells, the overexpression of GLUT2 protein was verified by 
Western Blot. GT1-7 cells do not express endogenous GLUT2 protein; GT1-7 cells 
transfected with pcDNA3.1-GLUT2 vector express high levels of GLUT2 protein; liver 
protein was used as a positive control (Figure 6). 
 Glucose Treatment of GT1-7GLUT2 and GT1-7pcDNA Cells 
After 16 h of incubation with glucose, cellular ATP levels were measured in GT1-
7GLUT2 cells and GT1-7pcDNA cells. As shown in Figure 7, glucose significantly increased 
cellular ATP in both GT1-7GLUT2 (p < 0.0001, one-way ANOVA) and GT1-7pcDNA cells (p < 
0.001, one-way ANOVA). In GT1-7pcDNA cells, ATP levels were significantly higher at 2.5 
mM glucose compared with 1 mM glucose, increasing glucose from 2.5 mM to 5, 10 and 25 
mM could not further increase ATP levels (p < 0.05, 1 mM vs. 2.5, 5, 10 and 25 mM 
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Figure 3. GLUT2 mRNA expression in the AP, NTS, ARC, VMN, PVN and LH in the two-
week 50% underfed rats and ad libitum fed rats. GLUT2 mRNA was significantly increased 
in the AP in underefed rats (p < 0.05). 
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Figure 4. GLUT2 mRNA response to glucose in ex vivo cultured AP/NTS tissue. Rat 
AP/NTS tissue was dissected and cultured in DMEM plus 2% FBS and 1 or 2.5 mM glucose 
at 37˚C for 3 h. GLUT2 mRNA in AP/NTS tissue was significantly increased by 1 mM 
glucose compared with 2.5 mM glucose (p < 0.05). 
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Figure 5. GLUT2 mRNA response to glucose in N1E-115 cell cutlute. N1E-115 cells were 
cultured in DMEM plus 2% FBS and 1, 2.5 and 5 mM glucose at 37˚C, 5% CO2 for 16 h. 
GLUT2 mRNA in N1E-115 cells was significantly decreased by glucose (p < 0.05); GLUT2 
mRNA was significantly higher at 1 mM glucose compared with 5 mM glucose (p < 0.05). 
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Figure 6. Western Blot showing overexpression of GLUT2 protein in GT1-7 cells. Lane 1: 
GT1-7GLUT2 cells; lane 2: GT1-7pcDNA cells; lane 3: rat liver control. 
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glucose, Tukey’s test). In GT1-7GLUT2 cells, ATP levels were significantly increased in a 
dose-dependent manner from 1 to 5 mM glucose, increasing glucose from 5 mM to 10 and 25 
mM could not further increase ATP levels (p < 0.05, 1 mM vs. 2.5, 5, 10 and 25 mM 
glucose, 2.5 mM vs. 5, 10 and 25 mM glucose, Tukey’s test). At 5, 10 and 25 mM glucose, 
ATP levels in GT1-7GLUT2 cells were significantly higher compared with GT1-7pcDNA cells (p 
< 0.001, t-test). 
AgRP mRNA response to glucose in GT1-7GLUT2 and GT1-7pcDNMA cells were shown 
in Figure 8. Glucose significantly decreased AgRP mRNA expression in both GT1-7pcDNA (p 
< 0.0001, one-way ANOVA) and GT1-7GLUT2 cells (p = 0.0007, one-way ANOVA). At 25 
mM glucose, AgRP mRNA was lowered to 56% of values at 1 mM glucose in GT1-7pcDNA 
cells, whereas AgRP mRNA was lowered to 37% of values at 1 mM glucose in GT1-7GLUT2 
cells. AgRP mRNA in GT1-7GLUT2 cells had a more sensitive response to higher glucose (25 
mM) compared with GT1-7pcDNA cells (p < 0.05, AgRP percentage value at 25 mM in GT1-
7GLUT2 vs GT1-7pcDNA cells, t-test). 
2DG Treatment of GT1-7GLUT2 and GT1-7pcDNA Cells 
In GT1-7pcDNA cells, 2DG induced about 200% increase in AgRP mRNA compared 
with no 2DG control (p = 0.0003, t-test). In GT1-7GLUT2 cells, 2DG induced about 35% 
increase in AgRP mRNA compared with no 2DG control (p = 0.0019, t-test). 2DG-
stimulated increase in AgRP mRNA in GT1-7GLUT2 cells was significantly smaller compared 
with GT1-7pcDNA cells (p = 0.003, t-test) (Figure 9A). After 24-h incubation with 2DG, the 
cellular ATP levels decreased by 40.2% (p < 0.0001, t-test) and 35.9% (p < 0.001, t-test) in 
GT1-7pcDNA and GT1-7GLUT2 cells, respectively, compared with no 2DG controls. 2DG 
induced depletion of cellular ATP was similar in both GT1-7GLUT2 and GT1-7pcDNA cells 
(Figure 9B).
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Figure 7. Cellular ATP response to glucose in GT1-7GLUT2 and GT1-7pcDNA cells. GT1-7GLUT2 
and GT1-7pcDNA Cells were cultured in DMEM plus 2% FBS and 1, 2.5, 5, 10 and 25 mM 
glucose at 37˚C, 5% CO2 for 16 h. Glucose significantly increased cellular ATP levels in 
both GT1-7GLUT2 (p < 0.0001) and GT1-7pcDNA cells (p < 0.001). At 5, 10 and 25 mM 
glucose, cellular ATP in GT1-7GLUT2 cells was significantly higher compared with GT1-
7pcDNA cells (p < 0.001). 
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Figure 8. AgRP mRNA response to glucose in GT1-7GLUT2 and GT1-7pcDNA cells. GT1-
7GLUT2 and GT1-7pcDNA Cells were cultured in DMEM plus 2% FBS and 1, 2.5, 5, 10 and 25 
mM glucose at 37˚C, 5% CO2 for 24 h. Glucose significantly decreased AgRP mRNA in 
both GT1-7GLUT2 (p < 0.001) and GT1-7pcDNA cells (p < 0.0001). At 25 mM glucose, AgRP 
mRNA was significantly lower in GT1-7GLUT2 cells compared with GT1-7pcDNA cells (p < 
0.05). 
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Figure 9. AgRP mRNA and cellular ATP responses to 2DG in GT1-7GLUT2 and GT1-7pcDNA 
cells. GT1-7GLUT2 and GT1-7pcDNA Cells were cultured in DMEM, 2% FBS, 2.5 mM glucose 
with or without 5 mM 2DG at 37˚C, 5% CO2 for 24 h. A. AgRP mRNA was significantly 
increased by 2DG in both GT1-7GLUT2 (p < 0.01) and GT1-7pcDNA cells (p < 0.001). 2DG-
induced AgRP mRNA was significantly less in GT1-7GLUT2 cells compared with GT1-7pcDNA 
cells (p < 0.01). B. 2DG significantly decreased cellular ATP levels in both GT1-7GLUT2 (p 
<0.001) and GT1-7pcDNA (p < 0.0001) cells. 2DG induced similar depletion of cellular ATP in 
both cells. 
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Discussion 
 In this study, we investigated the effect of energy status on brain GLUT2 expression 
and the effect of GLUT2 overexpression on energy status in neuronal cells. We found that in 
contrary to the peripheral tissue such as liver and pancreatic islets, brain GLUT2 mRNA was 
upregulated by low energy status. In vivo, we mimicked low energy status by 50% 
underfeeding rats for two weeks, during which period the animals lost more than 60 g of 
body weight compared with 40 g of body weight gain in the ad libitum fed controls. Serum 
glucose measured at the end of the experiment was not different between the two groups; 
however, one time point of blood glucose does not represent the fluctuation of blood glucose 
during the whole experiment, and it is apparent that body weight is a better index of low 
energy status than blood glucose here. In the underfed rats, GLUT2 mRNA was increased in 
the hindbrain area postrema compared with ad libitum fed rats. In ex vivo and in vitro, we 
mimicked low energy status and low glucose status by culturing tissue or cells in 1 mM 
glucose. In cultured rat AP/NTS tissue, GLUT2 mRNA was increased by 1 mM glucose 
compared with 2.5 mM glucose; in N1E-115 cells, GLUT2 mRNA was increased by 1 mM 
glucose compared with 5 mM glucose. The results from in vivo, ex vivo and in vitro 
consistently demonstrated that brain GLUT2 mRNA was upregulated by low energy status, 
which is opposite to peripheral tissue. In the liver and pancreatic islets, GLUT2 was 
decreased by fasting and increased by refeeding (Chen, Alam et al. 1990; Thorens, Flier et al. 
1990). In primary hepatocyte culture and isolated pancreatic islet culture, GLUT2 mRNA 
and protein were increased by high glucose such as 27.8 mM for hepatocytes and 16.7 mM 
for islets (Asano, Katagiri et al. 1992; Ferrer, Gomis et al. 1993; Rencurel, Waeber et al. 
1996). Previous work from our group had shown that GLUT2 mRNA was decreased in the 
hindbrain in Zucker fatty rats compared with lean controls (Bogacka, Roane et al. 2004); 1-h 
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refeeding reduced GLUT2 mRNA in both the hindbrain and the hypothalamus in 24-h 50% 
food restricted rats (Zhou, Roane et al. 2003), indicating that GLUT2 in the brain was 
downregulated by hyperlycemia or refeeding. The results from this study provided additional 
evidence to demonstrate that GLUT2 mRNA in the hindbrain area postrema was upregulated 
in long term underfed rats. Furthermore, we demonstrated that in AP/NTS tissue culture and 
in cell culture, GLUT2 mRNA was increased by low glucose (1 mM) compared with 2.5 or 5 
mM glucose, implicating that brain GLUT2 mRNA is directly regulated by glucose. 
Particularly, we have shown that lowering glucose concentrations does-dependently 
decreased intracellular ATP levels and simultaneously increased AgRP mRNA expression in 
the N1E-115 cell culture (Lee, Li et al. 2005). The neuronal cells detected the low energy 
status reflected by decreased ATP levels, and increased AgRP mRNA, which would have 
stimulated feeding in vivo. In the meantime, the neuronal cells increase the high Km GLUT2 
expression, and other molecules such as glucokinase (unpublished data), in order to increase 
the ability to process elevated glucose associated with feeding. In this sense, GLUT2 may 
play a role the brain glucose sensing.  
Of the six hypothalamic and hindbrain areas examined, only area postrema showed 
increased GLUT2 mRNA in underfed rats compared with control, suggesting that area 
postrema may play an important role in glucose sensing particularly sensing hunger. Previous 
studies have demonstrated that hindbrain but not the hypothalamus is essential for 
glucoprivation induced feeding. Injection of 5TG into the lateral cerebral ventricle failed to 
simulate feeding after blocking aqueduct connecting the third and fourth ventricle, whereas 
injection of 5TG into the fourth ventricle could still stimulate feeding, indicating that the 
hindbrain was necessary for stimulation of glucoprivic feeding (Ritter, Slusser et al. 1981; 
Penicaud, Pajot et al. 1990). Lesions of area postrema in the hindbrain blocked 5TG or 2DG 
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induced feeding, further suggesting that the area postrema is a critical area for glucoprivic 
feeding (Contreras, Fox et al. 1982; Bird, Cardone et al. 1983). Injection of 2DG or 5TG into 
the arcuate nucleus, ventromedial nucleus, paraventricular nucleus or lateral hypothalamus 
did not induce feeding and hyperglycemia (Miselis and Epstein 1975; Ritter, Dinh et al. 
2000). In contrast, injection of 5TG into the nucleus of the solitary tract, dorsomedial and 
ventrolateral medulla induced feeding and hyperglycemia (Ritter, Dinh et al. 2000). Taken 
together, hindbrain is necessary for response to glucoprivation. Our results are in agreement 
with these studies to implicate that hindbrain is more important for glucose sensing under 
low energy status than the hypothalamus. 
Next we investigated the effect of GLUT2 overexpression in neuronal cells, and 
found that GLUT2 overexpression resulted in a 20% elevation in cellular ATP when the cells 
were incubated with ambient glucose (5, 10, 25 mM) in the medium. GLUT3, which has a 
high affinity and low Km for glucose, is the major glucose transporter in neuronal tissues 
(Olson and Pessin 1996). At 5 mM and higher glucose levels, GLUT3 has already been 
saturated and intracellular glucose cannot further increase in proportional to extracellular 
glucose levels. Thus, glucose transport becomes rate limiting for glucose usage by neuronal 
cells, which is reflected by saturation of cellular ATP and glucose induced inhibition of 
AgRP at higher glucose levels. GLUT2 has a low affinity and high Km for glucose (Olson 
and Pessin 1996); after overexpressing GLUT2 in the neuronal cells, glucose transport is no 
longer rate limiting for glucose usage by the neuronal cells. GLUT2 overexpression allows 
increased glucose flux through glycolysis to generate ATP, resulting in higher cellular ATP 
levels and greater inhibition of AgRP at high glucose levels (25 mM glucose). Consistent 
with previous report, glucose dose dependently increases cellular ATP and decreases AgRP 
mRNA expression in both GT1-7GLUT2 cells and control GT12-7pcDNA cells (Lee, Li et al. 
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2005). The increase of ATP and decrease of AgRP mRNA by glucose was not strictly 
parallel, which suggests that ATP is not the only factor that affects AgRP expression, AMP-
activated protein kinase ( Minokoshi, Alquier et al. 2004; Lee, Li et al. 2005) and other 
unknown mediators may also be involved in the regulation of AgRP expression. 
2DG is a glucose analogue that can competitively inhibit glucose metabolism and 
induce glucoprivation (Brown 1962). GLUT2 overexpression in neuronal cells changes the 
cellular response not only to high glucose, but also to 2DG. Compared with GT1-7pcDNA 
cells, in which 2DG induced about 2-fold increase in AgRP mRNA expression, 2DG only 
stimulated 35% increase in AgRP mRNA in GT1-7GLUT2 cells. In contrast, 2DG induced 
similar depletion of cellular ATP in both cells. The induction of AgRP and depletion of ATP 
by 2DG treatment is consistent with our previous report, in which we have shown that 2DG 
increased AgRP mRNA in neuronal cell culture and ex vivo cultured mouse hypothalamus. 
We also showed that 2DG exerted the glucoprivic effect by decreasing cellular energy status, 
which is supported by the findings that 2DG dose-dependently reduced cellular ATP and 
supplement of pyruvate partially reversed the effect of 2DG on ATP and AgRP mRNA (Lee, 
Li et al. 2004). However, the discrepancy between the similar ATP depletion and 
significantly different stimulation of AgRP mRNA in both cells after 2DG treatment 
indicates that AgRP mRNA in the neuronal cells is also regulated by factors other than ATP, 
such factors could be AMP-activated protein kinase and probably factors unknown at present 
( Minokoshi, Alquier et al. 2004; Lee, Li et al. 2005). More work is needed before we can 
explain why GLUT2 overexpression attenuated 2DG stimulated AgRP mRNA in the 
neuronal cells.  
Previous study has reported that ICV injection of antisense oligos to GLUT2 mRNA 
(daily injection for 13 days) suppressed cumulative food intake and diminished the feeding 
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response to 2DG in rats compared with missense control (Wan, Hulsey et al. 1998). In 
another study, injection of antisense oligos to GLUT2 mRNA directly into the arcuate 
nucleus (twice per day for two days) reduced body weight without changing food intake, as 
well as eliminated insulin response induced by carotid artery injection of a small amount of 
glucose (Leloup, Orosco et al. 1998). These two studies showed that blocking brain GLUT2 
mRNA decreased food intake, increased energy expenditure or impaired brain-regulated 
insulin secretion. However, these studies neither confirmed that brain GLUT2 protein was 
reduced, nor identified in which brain area GLUT2 protein was reduced after antisense 
treatment. In addition, neither study examined the mechanism of how blocking GLUT2 
mRNA reduced food intake, such as whether arcuate neuropeptide was involved or due to 
other mechanisms. Our study showed that GLUT2 overexpression led to greater inhibition of 
AgRP in the presence of high glucose. Based on the in vitro study, we predict that 
overexpression of GLUT2 in the brain will lead to decreased hypothalamic AgRP expression 
and therefore decreased food intake, which appears to be contradictory to the conclusions of 
the above two studies. However, the results from in vivo study might be opposite to in vitro 
study due to the complex feedback, the adaptation systems in the animals, and the timing of 
the measurements. Unless the effect of GLUT2 overexpression in the brain and the involved 
mechanisms are examined, it is too early to speculate why both blocking and overexpressing 
GLUT2 in the brain appear to produce similar effect on food intake. 
 In this study, we provide evidence to indicate that GLUT2 is likely to play a role in 
the brain glucose sensing. We showed that brain GLUT2 mRNA was upregulated in response 
to low energy status (particularly to low glucose), and overexpresssion of GLUT2 increased 
energy status in neuronal cells, reflected by increased intracellular ATP levels and decreased 
hunger signals (AgRP mRNA) at high glucose concentrations, and attenuated AgRP response 
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to glucoprivation. Further work is needed to confirm if overexpression of GLUT2 in the 
brain will similarly enhance cellular energy status, suppress hunger signals and thereby 
reduce food intake in the animal studies. 
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CHAPTER 5 
CONCLUSIONS 
 
The work in this dissertation includes two parts. In the first part, we combined tissue 
micropunch technique and real time RT-PCR to quantify relative mRNA levels of multiple 
genes in specific brain nuclei. We demonstrated glucokinase (GK), glucose transporter 
GLUT2, sulfonylurea receptor-1 (SUR1), glucagon-like peptide-1 receptor (GLP-1R) and 
neuropeptide Y (NPY) mRNA expression in nine areas in the rat hypothalamus and 
hindbrain. The colocalization of GK, GLUT2, SUR1 and GLP-1R in the same areas in the 
hypothalamus and hindbrain implicates the presence of β cell glucose sensing mechanism in 
the brain; the colocalization of these genes with NPY in the arcuate nucleus suggests that the 
brain glucose sensing may play a role in the regulation of food intake. 
In the second part of this dissertation, we focused on the regulation of brain GLUT2 
by energy status and the effect of GLUT2 overexpression on energy status in neuronal cells. 
We showed that brain GLUT2 mRNA was upregulated in response to low energy status 
(particularly low glucose status) under three conditions: in vivo, ex vivo and in vitro. We 
further showed that overexpresssion of GLUT2 increased energy status in neuronal cells, 
decreased hunger signals (AgRP mRNA) at high glucose concentrations, and attenuated 
hunger signals (AgRP mRNA) induced by glucoprivation. We provide evidence to indicate 
that GLUT2 is likely to play a role in the brain glucose sensing, and brain glucose sensing 
appears to participate in the regulation of food intake. 
Further work is needed to confirm if overexpression of GLUT2 in the brain will 
similarly enhance cellular energy status, suppress hunger signals and thereby reduce food 
intake in the animal studies. The presence of other components of β cell glucose sensing 
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apparatus in the brain suggests that brain may use similar mechanism as β cells for glucose 
sensing; and instead of regulation of insulin secretion, brain glucose sensing may be involved 
in the regulation of energy homeostasis. Similar work on GK, another β cell glucose sensor, 
can be done as the work on GLUT2 in this dissertation, in order to understand better the 
mechanisms of brain glucose sensing and their involvement in the regulation of energy 
homeostasis.  
 
 
 
 
 72
REFERENCES 
 
Agius, L. and M. Peak (1993). "Intracellular binding of glucokinase in hepatocytes and 
translocation by glucose, fructose and insulin." Biochem J 296 (Pt 3): 785-96. 
Agius, L., M. Peak, et al. (1995). "The regulatory protein of glucokinase binds to the 
hepatocyte matrix, but, unlike glucokinase, does not translocate during substrate 
stimulation." Biochem J 309 (Pt 3): 711-3. 
Alvarez, E., I. Roncero, et al. (1996). "Expression of the glucagon-like peptide-1 receptor 
gene in rat brain." J Neurochem 66(3): 920-7. 
Alvarez, E., I. Roncero, et al. (2002). "Evidence that glucokinase regulatory protein is 
expressed and interacts with glucokinase in rat brain." J Neurochem 80(1): 45-53. 
Anand, B. K., G. S. Chhina, et al. (1964). "Activity Of Single Neurons In The Hypothalamic 
Feeding Centers: Effect Of Glucose." Am J Physiol 207: 1146-54. 
Andersson, U., K. Filipsson, et al. (2004). "AMP-activated protein kinase plays a role in the 
control of food intake." J Biol Chem 279(13): 12005-8. 
Andreone, T. L., R. L. Printz, et al. (1989). "The amino acid sequence of rat liver glucokinase 
deduced from cloned cDNA." J Biol Chem 264(1): 363-9. 
Asano, T., H. Katagiri, et al. (1992). "Upregulation of GLUT2 mRNA by glucose, mannose, 
and fructose in isolated rat hepatocytes." Diabetes 41(1): 22-5. 
Ashcroft, F. M. and F. M. Gribble (1998). "Correlating structure and function in ATP-
sensitive K+ channels." Trends Neurosci 21(7): 288-94. 
Bali, D., A. Svetlanov, et al. (1995). "Animal model for maturity-onset diabetes of the young 
generated by disruption of the mouse glucokinase gene." J Biol Chem 270(37): 21464-7. 
Bedoya, F. J., F. M. Matschinsky, et al. (1986). "Differential regulation of glucokinase 
activity in pancreatic islets and liver of the rat." J Biol Chem 261(23): 10760-4. 
Bertile, F., H. Oudart, et al. (2003). "Hypothalamic gene expression in long-term fasted rats: 
relationship with body fat." Biochem Biophys Res Commun 303(4): 1106-13. 
Bethesda, M. (1998). "National Institues of Health. Clinical guidelines on the identification, 
evaluation, and treatment of overweight and obesity in adults. National Institute of Health. 
Bethesda, MD: Department of Health and Human Services: National Institues of Helath; 
National Heart, Lung, and Blood Institute." 
 73
Bird, E., C. C. Cardone, et al. (1983). "Area postrema lesions disrupt food intake induced by 
cerebroventricular infusions of 5-thioglucose in the rat." Brain Res 270(1): 193-6. 
Bogacka, I., D. S. Roane, et al. (2004). "Expression levels of genes likely involved in 
glucose-sensing in the obese Zucker rat brain." Nutr Neurosci 7(2): 67-74. 
Borg, M. A., R. S. Sherwin, et al. (1997). "Local ventromedial hypothalamus glucose 
perfusion blocks counterregulation during systemic hypoglycemia in awake rats." J Clin 
Invest 99(2): 361-5. 
Borg, W. P., M. J. During, et al. (1994). "Ventromedial hypothalamic lesions in rats suppress 
counterregulatory responses to hypoglycemia." J Clin Invest 93(4): 1677-82. 
Borg, W. P., R. S. Sherwin, et al. (1995). "Local ventromedial hypothalamus glucopenia 
triggers counterregulatory hormone release." Diabetes 44(2): 180-4. 
Brant, A. M., T. J. Jess, et al. (1993). "Immunological analysis of glucose transporters 
expressed in different regions of the rat brain and central nervous system." Biochem Biophys 
Res Commun 192(3): 1297-302. 
Brown, J. (1962). "Effects of 2-deoxyglucose on carbohydrate metablism: review of the 
literature and studies in the rat." Metabolism 11: 1098-112. 
Brown, K. S., S. S. Kalinowski, et al. (1997). "Glucokinase regulatory protein may interact 
with glucokinase in the hepatocyte nucleus." Diabetes 46(2): 179-86. 
Chen, L., T. Alam, et al. (1990). "Regulation of beta-cell glucose transporter gene 
expression." Proc Natl Acad Sci U S A 87(11): 4088-92. 
Contreras, R. J., E. Fox, et al. (1982). "Area postrema lesions produce feeding deficits in the 
rat: effects of preoperative dieting and 2-deoxy-D-glucose." Physiol Behav 29(5): 875-84. 
Davis, J. D., D. Wirtshafter, et al. (1981). "Sustained intracerebroventricular infusion of brain 
fuels reduces body weight and food intake in rats." Science 212(4490): 81-3. 
de la Iglesia, N., M. Mukhtar, et al. (2000). "The role of the regulatory protein of glucokinase 
in the glucose sensory mechanism of the hepatocyte." J Biol Chem 275(14): 10597-603. 
de Vries, M. G., L. M. Arseneau, et al. (2003). "Extracellular glucose in rat ventromedial 
hypothalamus during acute and recurrent hypoglycemia." Diabetes 52(11): 2767-73. 
Drucker, D. J. (1998). "Glucagon-like peptides." Diabetes 47(2): 159-69. 
Drucker, D. J. (2001). "Minireview: the glucagon-like peptides." Endocrinol 142(2): 521-7. 
Dunn-Meynell, A. A., N. E. Rawson, et al. (1998). "Distribution and phenotype of neurons 
containing the ATP-sensitive K+ channel in rat brain." Brain Res 814(1-2): 41-54. 
 74
Dunn-Meynell, A. A., V. H. Routh, et al. (2002). "Glucokinase is the likely mediator of 
glucosensing in both glucose-excited and glucose-inhibited central neurons." Diabetes 51(7): 
2056-65. 
Farrelly, D., K. S. Brown, et al. (1999). "Mice mutant for glucokinase regulatory protein 
exhibit decreased liver glucokinase: a sequestration mechanism in metabolic regulation." 
Proc Natl Acad Sci U S A 96(25): 14511-6. 
Ferre, T., E. Riu, et al. (1996). "Evidence from transgenic mice that glucokinase is rate 
limiting for glucose utilization in the liver." Faseb J 10(10): 1213-8. 
Ferrer, J., R. Gomis, et al. (1993). "Signals derived from glucose metabolism are required for 
glucose regulation of pancreatic islet GLUT2 mRNA and protein." Diabetes 42(9): 1273-80. 
Garcia, M. A., C. Millan, et al. (2003). "Hypothalamic ependymal-glial cells express the 
glucose transporter GLUT2, a protein involved in glucose sensing." J Neurochem 86(3): 709-
24. 
Gehlert, D. R., B. M. Chronwall, et al. (1987). "Localization of neuropeptide Y messenger 
ribonucleic acid in rat and mouse brain by in situ hybridization." Synapse 1(1): 25-31. 
Girard, J., P. Ferre, et al. (1997). "Mechanisms by which carbohydrates regulate expression 
of genes for glycolytic and lipogenic enzymes." Annu Rev Nutr 17: 325-52. 
Grimsby, J., J. W. Coffey, et al. (2000). "Characterization of glucokinase regulatory protein-
deficient mice." J Biol Chem 275(11): 7826-31. 
Grimsby, J., R. Sarabu, et al. (2003). "Allosteric activators of glucokinase: potential role in 
diabetes therapy." Science 301(5631): 370-3. 
Guillam, M. T., P. Dupraz, et al. (2000). "Glucose uptake, utilization, and signaling in 
GLUT2-null islets." Diabetes 49(9): 1485-91. 
Guillam, M. T., E. Hummler, et al. (1997). "Early diabetes and abnormal postnatal pancreatic 
islet development in mice lacking Glut-2." Nat Genet 17(3): 327-30. 
Hagan, M. M., P. A. Rushing, et al. (2001). "Opioid receptor involvement in the effect of 
AgRP- (83-132) on food intake and food selection." Am J Physiol Regul Integr Comp 
Physiol 280(3): R814-21. 
Hagan, M. M., P. A. Rushing, et al. (2000). "Long-term orexigenic effects of AgRP-(83---
132) involve mechanisms other than melanocortin receptor blockade." Am J Physiol Regul 
Integr Comp Physiol 279(1): R47-52. 
Hahn, T. M., J. F. Breininger, et al. (1998). "Coexpression of Agrp and NPY in fasting-
activated hypothalamic neurons." Nat Neurosci 1(4): 271-2. 
 75
Hardie, D. G., D. Carling, et al. (1998). "The AMP-activated/SNF1 protein kinase subfamily: 
metabolic sensors of the eukaryotic cell?" Annu Rev Biochem 67: 821-55. 
Heimberg, H., A. De Vos, et al. (1996). "The glucose sensor protein glucokinase is expressed 
in glucagon-producing alpha-cells." Proc Natl Acad Sci U S A 93(14): 7036-41. 
Heimberg, H., A. De Vos, et al. (1995). "Differences in glucose transporter gene expression 
between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport 
but not in glucose utilization." J Biol Chem 270(15): 8971-5. 
Hughes, S. D., C. Quaade, et al. (1993). "Transfection of AtT-20ins cells with GLUT-2 but 
not GLUT-1 confers glucose-stimulated insulin secretion. Relationship to glucose 
metabolism." J Biol Chem 268(20): 15205-12. 
Huszar, D., C. A. Lynch, et al. (1997). "Targeted disruption of the melanocortin-4 receptor 
results in obesity in mice." Cell 88(1): 131-41. 
Jetton, T. L., Y. Liang, et al. (1994). "Analysis of upstream glucokinase promoter activity in 
transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain 
and gut." J Biol Chem 269(5): 3641-54. 
Johnson, J. H., A. Ogawa, et al. (1990). "Underexpression of beta cell high Km glucose 
transporters in noninsulin-dependent diabetes." Science 250(4980): 546-9. 
Karschin, C., C. Ecke, et al. (1997). "Overlapping distribution of K(ATP) channel-forming 
Kir6.2 subunit and the sulfonylurea receptor SUR1 in rodent brain." FEBS Lett 401(1): 59-
64. 
Khong, K., S. E. Kurtz, et al. (2001). "Expression of functional melanocortin-4 receptor in 
the hypothalamic GT1-1 cell line." Neuroendocrinol 74(3): 193-201. 
Kieffer, T. J. and J. F. Habener (2000). "The adipoinsular axis: effects of leptin on pancreatic 
beta-cells." Am J Physiol Endocrinol Metab 278(1): E1-E14. 
Kim, E. K., I. Miller, et al. (2004). "C75, a fatty acid synthase inhibitor, reduces food intake 
via hypothalamic AMP-activated protein kinase." J Biol Chem 279(19): 19970-6. 
Kim, M. S., J. Y. Park, et al. (2004). "Anti-obesity effects of alpha-lipoic acid mediated by 
suppression of hypothalamic AMP-activated protein kinase." Nat Med 10(7): 727-33. 
Landree, L. E., A. L. Hanlon, et al. (2004). "C75, a fatty acid synthase inhibitor, modulates 
AMP-activated protein kinase to alter neuronal energy metabolism." J Biol Chem 279(5): 
3817-27. 
Larsen, P. J., M. Tang-Christensen, et al. (1997). "Central administration of glucagon-like 
peptide-1 activates hypothalamic neuroendocrine neurons in the rat." Endocrinology 138(10): 
4445-55. 
 76
Lee, K., A. K. Dixon, et al. (1999). "Glucose-receptive neurones in the rat ventromedial 
hypothalamus express KATP channels composed of Kir6.1 and SUR1 subunits." J Physiol 
515 (Pt 2): 439-52. 
Lee, K., B. Li, et al. (2005). "The Role of Neuronal Energy Status in the Regulation of AMP-
activated Protein Kinase, Orexigenic Neuropeptides Expression and Feeding Behavior." 
Endocrinol 146:3-10. 
Leloup, C., M. Arluison, et al. (1994). "Glucose transporter 2 (GLUT 2): expression in 
specific brain nuclei." Brain Res 638(1-2): 221-6. 
Leloup, C., M. Orosco, et al. (1998). "Specific inhibition of GLUT2 in arcuate nucleus by 
antisense oligonucleotides suppresses nervous control of insulin secretion." Brain Res Mol 
Brain Res 57(2): 275-80. 
Levin, B. E. (2001). "Glucosensing neurons do more than just sense glucose." Int J Obes 
Relat Metab Disord 25 Suppl 5: S68-72. 
Levin, B. E., A. A. Dunn-Meynell, et al. (1999). "Brain glucose sensing and body energy 
homeostasis: role in obesity and diabetes." Am J Physiol 276(5 Pt 2): R1223-31. 
Li, B., X. Xi, et al. (2003). "Distribution of glucokinase, glucose transporter GLUT2, 
sulfonylurea receptor-1, glucagon-like peptide-1 receptor and neuropeptide Y messenger 
RNAs in rat brain by quantitative real time RT-PCR." Brain Res Mol Brain Res 113(1-2): 
139-42. 
Liu, G. J., A. M. Simpson, et al. (2003). "ATP-sensitive potassium channels induced in liver 
cells after transfection with insulin cDNA and the GLUT 2 transporter regulate glucose-
stimulated insulin secretion." Faseb J 17(12): 1682-4. 
Loftus, T. M., D. E. Jaworsky, et al. (2000). "Reduced food intake and body weight in mice 
treated with fatty acid synthase inhibitors." Science 288(5475): 2379-81. 
Lynch, R. M., L. S. Tompkins, et al. (2000). "Localization of glucokinase gene expression in 
the rat brain." Diabetes 49(5): 693-700. 
Magnuson, M. A., T. L. Andreone, et al. (1989). "Rat glucokinase gene: structure and 
regulation by insulin." Proc Natl Acad Sci U S A 86(13): 4838-42. 
Magnuson, M. A. and K. D. Shelton (1989). "An alternate promoter in the glucokinase gene 
is active in the pancreatic beta cell." J Biol Chem 264(27): 15936-42. 
Matschinsky, F., Y. Liang, et al. (1993). "Glucokinase as pancreatic beta cell glucose sensor 
and diabetes gene." J Clin Invest 92(5): 2092-8. 
Mellon, P. L., J. J. Windle, et al. (1990). "Immortalization of hypothalamic GnRH neurons 
by genetically targeted tumorigenesis." Neuron 5(1): 1-10. 
 77
Merchenthaler, I., M. Lane, et al. (1999). "Distribution of pre-pro-glucagon and glucagon-
like peptide-1 receptor messenger RNAs in the rat central nervous system." J Comp Neurol 
403(2): 261-80. 
Miki, T., B. Liss, et al. (2001). "ATP-sensitive K+ channels in the hypothalamus are essential 
for the maintenance of glucose homeostasis." Nat Neurosci 4(5): 507-12. 
Minokoshi, Y., T. Alquier, et al. (2004). "AMP-kinase regulates food intake by responding to 
hormonal and nutrient signals in the hypothalamus." Nature 428(6982): 569-74. 
Miselis, R. R. and A. N. Epstein (1975). "Feeding induced by intracerebroventricular 2-
deoxy-D-glucose in the rat." Am J Physiol 229(5): 1438-47. 
Mizuno, T. M., H. Makimura, et al. (1999). "Fasting regulates hypothalamic neuropeptide Y, 
agouti-related peptide, and proopiomelanocortin in diabetic mice independent of changes in 
leptin or insulin." Endocrinology 140(10): 4551-7. 
Mizuno, T. M. and C. V. Mobbs (1999). "Hypothalamic agouti-related protein messenger 
ribonucleic acid is inhibited by leptin and stimulated by fasting." Endocrinology 140(2): 814-
7. 
Mizuno, Y. and Y. Oomura (1984). "Glucose responding neurons in the nucleus tractus 
solitarius of the rat: in vitro study." Brain Res 307(1-2): 109-16. 
Mobbs, C. V., L. M. Kow, et al. (2001). "Brain glucose-sensing mechanisms: ubiquitous 
silencing by aglycemia vs. hypothalamic neuroendocrine responses." Am J Physiol 
Endocrinol Metab 281(4): E649-54. 
Morris, B. J. (1989). "Neuronal localisation of neuropeptide Y gene expression in rat brain." 
J Comp Neurol 290(3): 358-68. 
Navarro, M., F. Rodriquez de Fonseca, et al. (1996). "Colocalization of glucagon-like 
peptide-1 (GLP-1) receptors, glucose transporter GLUT-2, and glucokinase mRNAs in rat 
hypothalamic cells: evidence for a role of GLP-1 receptor agonists as an inhibitory signal for 
food and water intake." J Neurochem 67(5): 1982-91. 
NHANES (1996). "National Center for Health statistics. Third National Health and Nutrition 
Examination Survey 1988-1994. Atlanta, GA: Centers for Disease Control and Prevention." 
NHANES (1999). "National Center for Health Statistics. NHANES 1999-2001, Prevenlence 
of overweight and obesity among adults, United States." 
Noma, Y., S. Bonner-Weir, et al. (1996). "Translocation of glucokinase in pancreatic beta-
cells during acute and chronic hyperglycemia." Endocrinol 137(4): 1485-91. 
Ollmann, M. M., B. D. Wilson, et al. (1997). "Antagonism of central melanocortin receptors 
in vitro and in vivo by agouti-related protein." Science 278(5335): 135-8. 
 78
Olson, A. L. and J. E. Pessin (1996). "Structure, function, and regulation of the mammalian 
facilitative glucose transporter gene family." Annu Rev Nutr 16: 235-56. 
Oomura, Y. (1983). "Glucose as a regulator of neuronal activity." Adv Metab Disord 10: 31-
65. 
Oomura, Y., K. Kimura, et al. (1964). "Reciprocal activities of the ventromedial and lateral 
hypothalamic areas of cats." Science 143: 484-5. 
Orci, L., M. Ravazzola, et al. (1990). "Evidence that down-regulation of beta-cell glucose 
transporters in non-insulin-dependent diabetes may be the cause of diabetic hyperglycemia." 
Proc Natl Acad Sci U S A 87(24): 9953-7. 
Palkovits, M. and M. J. Brownstein (1988). Maps and Guides to Microdissection of the Rat 
Brain. New York, Elservier. 
Paxinos, G. and C. Waston (1998). The Rat Brain in Stereotaxic Coordinates. San Diego, 
Academic Press. 
Penicaud, L., C. Leloup, et al. (2002). "Brain glucose sensing mechanism and glucose 
homeostasis." Curr Opin Clin Nutr Metab Care 5(5): 539-43. 
Penicaud, L., M. T. Pajot, et al. (1990). "Evidence that receptors controlling growth hormone 
and hyperglycemic responses to glucoprivation are located in the hindbrain." Endocr Res 
16(4): 461-75. 
Postic, C. and M. A. Magnuson (1999). "[Role of glucokinase (GK) in the maintenance of 
glucose homeostasis. Specific disruption of the gene by the Cre-loxP technique]." Journ 
Annu Diabetol Hotel Dieu: 115-24. 
Postic, C., M. Shiota, et al. (2001). "Cell-specific roles of glucokinase in glucose 
homeostasis." Recent Prog Horm Res 56: 195-217. 
Postic, C., M. Shiota, et al. (1999). "Dual roles for glucokinase in glucose homeostasis as 
determined by liver and pancreatic beta cell-specific gene knock-outs using Cre 
recombinase." J Biol Chem 274(1): 305-15. 
Qian, S., H. Chen, et al. (2002). "Neither agouti-related protein nor neuropeptide Y is 
critically required for the regulation of energy homeostasis in mice." Mol Cell Biol 22(14): 
5027-35. 
Rencurel, F., G. Waeber, et al. (1996). "Requirement of glucose metabolism for regulation of 
glucose transporter type 2 (GLUT2) gene expression in liver." Biochem J 314 (Pt 3): 903-9. 
Riediger, T., H. A. Schmid, et al. (2002). "Amylin and glucose co-activate area postrema 
neurons of the rat." Neurosci Lett 328(2): 121-4. 
 79
Ritter, R. C., P. G. Slusser, et al. (1981). "Glucoreceptors controlling feeding and blood 
glucose: location in the hindbrain." Science 213(4506): 451-2. 
Ritter, S., T. T. Dinh, et al. (2000). "Localization of hindbrain glucoreceptive sites 
controlling food intake and blood glucose." Brain Res 856(1-2): 37-47. 
Roth, J. D., D. K. Yee, et al. (2002). "Modeling the pathways of energy balance using the 
N1E-115 murine neuroblastoma cell line." Brain Res Mol Brain Res 103(1-2): 146-50. 
Sanders, N. M., A. A. Dunn-Meynell, et al. (2004). "Third ventricular alloxan reversibly 
impairs glucose counterregulatory responses." Diabetes 53(5): 1230-6. 
Schuit, F. C., P. Huypens, et al. (2001). "Glucose sensing in pancreatic beta-cells: a model 
for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus." Diabetes 
50(1): 1-11. 
Schwartz, M. W., S. C. Woods, et al. (2000). "Central nervous system control of food 
intake." Nature 404(6778): 661-71. 
Scott, D. K., J. J. Collier, et al. (2003). "A modest glucokinase overexpression in the liver 
promotes fed expression levels of glycolytic and lipogenic enzyme genes in the fasted state 
without altering SREBP-1c expression." Mol Cell Biochem 254(1-2): 327-37. 
Scrocchi, L. A., T. J. Brown, et al. (1996). "Glucose intolerance but normal satiety in mice 
with a null mutation in the glucagon-like peptide 1 receptor gene." Nat Med 2(11): 1254-8. 
Scrocchi, L. A., B. A. Marshall, et al. (1998). "Identification of glucagon-like peptide 1 
(GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor 
signaling." Diabetes 47(4): 632-9. 
Sergeyev, V., C. Broberger, et al. (2000). "Effect of 2-mercaptoacetate and 2-deoxy-D-
glucose administration on the expression of NPY, AGRP, POMC, MCH and 
hypocretin/orexin in the rat hypothalamus." Neuroreport 11(1): 117-21. 
Shimada, M., N. A. Tritos, et al. (1998). "Mice lacking melanin-concentrating hormone are 
hypophagic and lean." Nature 396(6712): 670-4. 
Shutter, J. R., M. Graham, et al. (1997). "Hypothalamic expression of ART, a novel gene 
related to agouti, is up-regulated in obese and diabetic mutant mice." Genes Dev 11(5): 593-
602. 
Silver, I. A. and M. Erecinska (1994). "Extracellular glucose concentration in mammalian 
brain: continuous monitoring of changes during increased neuronal activity and upon 
limitation in oxygen supply in normo-, hypo-, and hyperglycemic animals." J Neurosci 14(8): 
5068-76. 
Silver, I. A. and M. Erecinska (1998). "Glucose-induced intracellular ion changes in sugar-
sensitive hypothalamic neurons." J Neurophysiol 79(4): 1733-45. 
 80
Slosberg, E. D., U. J. Desai, et al. (2001). "Treatment of type 2 diabetes by adenoviral-
mediated overexpression of the glucokinase regulatory protein." Diabetes 50(8): 1813-20. 
Song, Z., B. E. Levin, et al. (2001). "Convergence of pre- and postsynaptic influences on 
glucosensing neurons in the ventromedial hypothalamic nucleus." Diabetes 50(12): 2673-81. 
Spanswick, D., M. A. Smith, et al. (1997). "Leptin inhibits hypothalamic neurons by 
activation of ATP-sensitive potassium channels." Nature 390(6659): 521-5. 
Spanswick, D., M. A. Smith, et al. (2000). "Insulin activates ATP-sensitive K+ channels in 
hypothalamic neurons of lean, but not obese rats." Nat Neurosci 3(8): 757-8. 
Stubbs, M., S. Aiston, et al. (2000). "Subcellular localization, mobility, and kinetic activity of 
glucokinase in glucose-responsive insulin-secreting cells." Diabetes 49(12): 2048-55. 
Terauchi, Y., H. Sakura, et al. (1995). "Pancreatic beta-cell-specific targeted disruption of 
glucokinase gene. Diabetes mellitus due to defective insulin secretion to glucose." J Biol 
Chem 270(51): 30253-6. 
Thorens, B. (2001). "GLUT2 in pancreatic and extra-pancreatic gluco-detection (review)." 
Mol Membr Biol 18(4): 265-73. 
Thorens, B., N. Deriaz, et al. (1996). "Protein kinase A-dependent phosphorylation of 
GLUT2 in pancreatic beta cells." J Biol Chem 271(14): 8075-81. 
Thorens, B., J. S. Flier, et al. (1990). "Differential regulation of two glucose transporters in 
rat liver by fasting and refeeding and by diabetes and insulin treatment." Diabetes 39(6): 712-
9. 
Thorens, B., M. T. Guillam, et al. (2000). "Transgenic reexpression of GLUT1 or GLUT2 in 
pancreatic beta cells rescues GLUT2-null mice from early death and restores normal glucose-
stimulated insulin secretion." J Biol Chem 275(31): 23751-8. 
Thorens, B., H. K. Sarkar, et al. (1988). "Cloning and functional expression in bacteria of a 
novel glucose transporter present in liver, intestine, kidney, and beta-pancreatic islet cells." 
Cell 55(2): 281-90. 
Tiedge, M. and S. Lenzen (1995). "Effects of glucose refeeding and glibenclamide treatment 
on glucokinase and GLUT2 gene expression in pancreatic B-cells and liver from rats." 
Biochem J 308 (Pt 1): 139-44. 
Tiedge, M., H. Steffeck, et al. (1999). "Metabolic regulation, activity state, and intracellular 
binding of glucokinase in insulin-secreting cells." Diabetes 48(3): 514-23. 
Turton, M. D., D. O'Shea, et al. (1996). "A role for glucagon-like peptide-1 in the central 
regulation of feeding." Nature 379(6560): 69-72. 
 81
Unger, R. H. (1991). "Diabetic hyperglycemia: link to impaired glucose transport in 
pancreatic beta cells." Science 251(4998): 1200-5. 
Van Schaftingen, E. (1994). "Short-term regulation of glucokinase." Diabetologia 37 Suppl 
2: S43-7. 
Van Schaftingen, E., M. Detheux, et al. (1994). "Short-term control of glucokinase activity: 
role of a regulatory protein." Faseb J 8(6): 414-9. 
Velho, G. and P. Froguel (1998). "Genetic, metabolic and clinical characteristics of maturity 
onset diabetes of the young." Eur J Endocrinol 138(3): 233-9. 
Wan, H. Z., M. G. Hulsey, et al. (1998). "Intracerebroventricular administration of antisense 
oligodeoxynucleotide against GLUT2 glucose transporter mRNA reduces food intake, body 
weight change and glucoprivic feeding response in rats." J Nutr 128(2): 287-91. 
Wolf, C. and M. Tanner (2002). "Obesity." West J Med 176(1): 23-8. 
Yang, X. J., L. M. Kow, et al. (1999). "Hypothalamic glucose sensor: similarities to and 
differences from pancreatic beta-cell mechanisms." Diabetes 48(9): 1763-72. 
Yang, X. J., L. M. Kow, et al. (2004). "Metabolic pathways that mediate inhibition of 
hypothalamic neurons by glucose." Diabetes 53(1): 67-73. 
Zhou, J., D. S. Roane, et al. (2003). "Short-term food restriction and refeeding alter 
expression of genes likely involved in brain glucosensing." Exp Biol Med (Maywood) 
228(8): 943-50. 
  
 
 82
 
APPENDIX 
 
LETTER OF PERMISSION 
 
 
23 November 2004 Our ref: HG/HDN/NOV04/J140 
  
 
Bing Li 
C/O Mr Roy J Martin 
Neurobiobehaviour Laboratory 
Pennington Biomedical Research 
Baton Rouge, 70802 
USA 
 
Dear Mr Martin 
 
MOLECULAR BRAIN RESEARCH, Vol 113, 2003, pp 139 – 142, R J Martin et al, “Distribution…” 
 
As per your letter dated 17th November 2004, we hereby grant you permission to reprint the aforementioned material at no charge in 
your thesis subject to the following conditions: 
 
1. If any part of the material to be used (for example, figures) has appeared in our publication with credit or acknowledgement 
to another source, permission must also be sought from that source.  If such permission is not obtained then that material 
may not be included in your publication/copies. 
 
2. Suitable acknowledgment to the source must be made, either as a footnote or in a reference list at the end of your 
publication, as follows: 
 
“Reprinted from Publication title, Vol number, Author(s), Title of article, Pages No., Copyright (Year), with permission 
from Elsevier”. 
 
3. Reproduction of this material is confined to the purpose for which permission is hereby given. 
 
4. This permission is granted for non-exclusive world English rights only.  For other languages please reapply separately for 
each one required.  Permission excludes use in an electronic form.  Should you have a specific electronic project in mind 
please reapply for permission. 
 
5. This includes permission for UMI to supply single copies, on demand, of the complete thesis.  Should your thesis be 
published commercially, please reapply for permission. 
 
Yours sincerely 
 
Helen Gainford 
Rights Manager 
 83
VITA 
 
Bing Li was born on April 26, 1971, in TianJin, People’s Republic of China. She 
attended elementary school from 1978 to 1984, middle school from 1984 to 1987, and high 
school from 1987 to 1990. In 1990, she was admitted into the seven-year program of TianJin 
Medical University to study medicine. She spent the first two years in the Department of 
Biology, NanKai University, for pre-med study, the next four years in TianJin Medical 
University for medical study, and the last year in The Department of Endocrinology, General 
Hospital of TianJin Medical University working on her thesis. In 1997, she graduated from 
TianJin Medical University as Master of Medicine. From 1997 to 2000, she worked in the 
Department of Medical Microbiology in TianJin Medical University as an instructor. She 
taught medical microbiology and at the same time was involved in a couple of research 
projects. To improve herself in the academic and research field, she went back to school for 
doctoral study starting from June 2000. Majoring in nutrition, she followed Dr Roy J Martin 
in U.S. as a graduate student, in the Department of Foods and Nutrition at the University of 
Georgia for the first year, and in the School of Human Ecology at Louisiana State University 
for the rest of her advanced study. Upon graduation, she will work in a postdoctoral position 
in related fields for several years. She hopes she will develop into a scientific researcher and 
an educator in the future.  
 84
